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ABSTRACT 
Tumorigenesis is a consequence of inactivating mutations of tumor suppressor genes and 
activating mutations of proto-oncogenes. Most of the mutations compromise cell 
autonomous and non-autonomous restrains on cell proliferation by modulating kinase 
signal transduction pathways. LKB1 is a tumor suppressor kinase whose sporadic 
mutations are frequently found in non-small cell lung cancer and cervical cancer. Germ-
line mutations in the LKB1 gene lead to Peutz-Jeghers syndrome with an increased risk of 
cancer and development of benign gastrointestinal hamartomatous polyps consisting of 
hyperproliferative epithelia and prominent stromal stalk composed of smooth muscle cell 
lineage cells. The tumor suppressive function of LKB1 is possibly mediated by 14 
identified LKB1 substrate kinases, whose activation is dependent on the LKB1 kinase 
complex. The aim of my thesis was to identify cell signaling pathways crucial for tumor 
suppression by LKB1.  
 
Re-introduction of LKB1 expression in the melanoma cell line G361 induces cell cycle 
arrest. Here we demonstrated that restoring the cytoplasmic LKB1 was sufficient to 
induce the cell cycle arrest in a tumor suppressor p53 dependent manner. To address the 
role of LKB1 in gastrointestinal tumor suppression, Lkb1 was deleted specifically in 
SMC lineage in vivo, which was sufficient to cause Peutz-Jeghers syndrome type 
polyposis. Studies on primary myofibroblasts lacking Lkb1 suggest that the regulation of 
TGFβ signaling, actin stress fibers and smooth muscle cell lineage differentiation are 
candidate mechanisms for tumor suppression by LKB1 in the gastrointestinal stroma. 
Further studies with LKB1 substrate kinase NUAK2 in HeLa cells indicate that NUAK2 
is part of a positive feedback loop by which NUAK2 expression promotes actin stress 
fiber formation and, reciprocally the induction of actin stress fibers promote NUAK2 
expression. Findings in this thesis suggest that p53 and TGFβ signaling pathways are 
potential mediators of tumor suppression by LKB1. An indication of NUAK2 in the 
promotion of actin stress fibers suggests that NUAK2 is one possible mediator of LKB1 
dependent TGFβ signaling and smooth muscle cell lineage differentiation.  
                               Introduction  
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INTRODUCTION 
Tumorigenesis is a condition of uncontrolled cell proliferation. Recently, it has become 
evident that tumors should not be considered as independent entities composed entirely of 
tumor cells but instead as complex tissues. For example, epithelial tumors are comprised 
of hyperproliferative epithelial cells that reciprocally interact with altered stroma 
consisting of fibroblasts, immune cells and vasculature 1. Tumor cells can be relieved 
from the restrains set by cell extrinsic and intrinsic tumor suppression. However, for this 
to occur, multiple loss-of-function mutations of tumor suppressor genes and dominant 
activating mutations of proto-oncogenes (called oncogenes subsequent to activating 
mutation) are required. Hereditary cancer syndromes have provided a valuable tool for 
the identification of several tumor suppressor genes that include adenomatous polyposis 
coli (APC) tumor suppressor whose hereditary mutations are causative of familial 
adenomatous polyposis coli 2, 3. The LKB1 tumor suppressor kinase was cloned in 1998 in 
the search for a cause of Peutz-Jeghers syndrome (PJS), a syndrome that is characterized 
by an increased risk of cancers and gastrointestinal (GI) polyposis 4, 5. Subsequently, 
LKB1 was identified as being frequently mutated in non-small cell lung cancer (NSCLC) 
and especially in lung adenocarcinomas 6, 7. In my thesis work I have studied the 
signaling networks and cellular functions that are essential for tumor suppression by 
LKB1. In the literature review I will first discuss the role of tumor suppressors and 
oncogenes in regulating the cell division cycle and tumor stroma interactions. 
Accordingly, special focus is laid on p53 and transforming growth factor β (TGFβ) tumor 
suppressor signaling, which mediate cell autonomous and non-autonomous tumor 
suppression, respectively 8, 9. Both p53 and TGFβ are also central to this thesis work. 
Finally, genetic evidence for tumor suppression by LKB1, LKB1 signaling network, and 
suggested tumor suppressive functions of LKB1 are presented. The most recent 
publications that complement or contrast the results presented in this thesis are discussed 
in the results and discussion section. 
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REVIEW OF LITERATURE 
1. Tumor suppressors inhibit kinase signal transduction pathways and cell 
proliferation 
1.1 Kinases are central mediators of cell growth 
Cell growth is triggered by external mitogenic cues, which induce multiple cell signal 
transduction pathways that relay the signals from the cell surface to exert their effects on, 
inter alia, cell division and protein translation machinery in the nucleus and in the 
cytoplasm, respectively 10. Cell signaling takes place in protein complexes in which the 
signal is delivered by various means to modify activity and/or localization of enzymes 
and transcription factors (TF) 11, 12. These changes are achieved by the regulated 
production and release of second messengers, such as phospholipids and calcium, and/or 
by covalent modifications of proteins by phosphorylation among other things 11, 12.  
 
Signaling pathways that are essential in cell growth and tumorigenesis are characterized 
by kinase cascades. The human genome encodes 518 kinases that comprise 90 tyrosine 
kinases and 428 serine/threonine kinases, which together constitute about 2% of human 
genes 13. Almost half of the kinases, such as epidermal growth factor receptor (EGFR) 
and protein kinase B (PKB/AKT) are located in genetic loci linked to cancer or other 
diseases, which highlights the immense importance of this class of proteins 
(www.sanger.ac.uk/genetics/CGP/Census/) 13, 14. Indeed, kinase domain encoding genes 
are the most prevalent group of genes indicated in tumorigenesis 14. Kinases 
phosphorylate tyrosine (Tyr), serine (S), and threonine (T) residues, which may regulate 
allosteric conformation of proteins or protein-protein interactions and thus have an effect 
on the activity of the target protein 11, 15. There are also approximately 50 pseudokinases 
encoded by the human genome, which are inactive due to substitution of at least one 
conserved residue in the kinase domain of these proteins 13. Pseudokinases have been 
indicated in the regulation of conformation and activity of proteins 16. Accordingly, 
multiple kinases with intact kinase domains, such as RAF-1, B-RAF, and discoidin 
domain receptor 1 (DDR1), have also been reported to possess kinase activity 
independent functions 17-19. 
                               Review of literature  
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1.2 Growth factor signaling is inhibited by a variety of tumor suppressors 
Many of the proto-oncogenes mediate growth factor (GF) signaling, whereas the role of 
the tumor suppressors involved is to ensure that these signals are transient (Figure 1). 
Tumor suppressor signaling dominates in conditions in which the cell is not capable of 
exerting a cell division without a risk of severe genetic perturbations 10. Prototypical GF 
signaling, such as EGFR signaling will be depicted below as an example of interactions 
between proto-oncogenes and tumor suppressors (Figure 1). Most of the growth 
promoting GF receptors (GFRs) are tyrosine kinases. In the event of oncogenic mutations 
or increased expression of GFs by the tumors themselves, the tyrosine kinases are 
constitutively activated and thus become independent of GF signaling from adjacent 
normal tissue 20. Upon GFR activity proto-oncogene RAS, which is frequently mutated in 
cancers, is recruited in the vicinity of the GFR 21. RAS is a small Guanosine-5'-
triphosphate hydrolase (GTPase), which in its GTP bound form activates its effector 
proteins that include the proto-oncogene phosphatidylinositol-3 kinase (PI3K) 22 and also 
the RAF kinases 23-26. RAS GTPase activating proteins (RAS-GAP), such as tumor 
suppressor neurofibromatosis 1 (NF1), induce the intrinsic GTPase hydrolyze activity of 
RAS, which leads to the inactivation of the RAS 27-31. RAS effector PI3K 22 
phosphorylates phosphatidylinositol lipids and is counteracted by tumor suppressor 
phosphatase tensin homologue (PTEN) 32-35. Under conditions of high PI3K and low 
PTEN activity proto-oncogene protein kinase B is activated (PKB1-3/AKT1-3) 36, 37. 
Active PKB phosphorylates and thus inactivates the pro-apoptotic proteins 38, 39, tumor 
suppressors of forkhead box class O (FoxO) family of transcription factors (TF) 40, 41, 
glycogen synthase kinase-3 (GSK3) 42, tumor suppressor p21Cip1/WAF1 43, 44, tumor 
suppressor p27Kip1 45, 46 and tumor suppressor tuberous sclerosis complex 2 (TSC2) 47. 
These phosphorylation events promote cell survival, cell proliferation and protein 
translation. The downstream signaling pathways of EGFR and RAS with their multiple 
points of negative regulation are fine examples of complex networks of proto-oncogenes 
and tumor suppressors. The identities of mutated genes in single tumors vary especially 
between tumor types, which could reflect tissue specific differences in expression and 
activity of tumor suppressors and proto-oncogenes.   
Review of literature 
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Figure 1: Signaling network of proto-oncogenes and tumor suppressors downstream of 
epidermal growth factor (EGF).  
EGF signaling is an example of a signaling network that promotes: cell proliferation, protein 
translation, and cell survival. The network includes multiple proteins that have been indicated in 
cancer. Several less-characterized connections between depicted downstream pathways of EGF 
have also been reported but omitted from figure 1 for clarity. However, an intriguing suggestion for 
the activation of TSC2 by LKB1 signaling has been included and marked with dim colors (see 
5.1). *= tumor suppressors and proto-oncogenes whose genetic alterations have been indicated 
in tumorigenesis (http://www.sanger.ac.uk/genetics/CGP/ Census 14 ) are marked with red and 
green, respectively. Proteins indicated in tumorigenesis but whose genetic alterations have not 
been identified in tumors are in blue. See text for references.
 
1.3 Tumor suppression by p53 
Whereas multiple tumor suppressors such as PTEN suppress GF signaling, tumor 
suppressor p53 induces cell cycle arrest, senescence, autophagy or apoptosis in response 
to cell intrinsic stress, such as DNA damage 9. Most of the p53 responses are credited to 
                               Review of literature  
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its ability to function as a transcription factor 48. The induction of transcription of 
p21cip/waf cyclin-dependent kinase (CDK) inhibitor has consistently been suggested to be 
critical for p53 induced cell cycle arrest 49, 50 (Figure 2). Moreover, p53 mutated cells are 
not arrested upon DNA damage and thus accumulate mutations and genome 
rearrangements at an increasing rate, which provides material for selection of tumorigenic 
properties 51-53. Indeed, hereditary p53 mutations are causative for Li-Fraumeni 
syndrome, which is characterized by an increased risk of cancer in several organs 54, 55. A 
large fraction of sporadic cancers also carry mutations of p53 or p53 signaling pathway 
components highlighting the importance of intact p53 responses (http://www-p53.iarc.fr/) 
56, 57. Consistent with the critical role of p53 in tumor suppression, re-activation of p53 in 
mouse models of various cancers has been shown to lead to apoptosis, cell senescence or 
cell cycle arrest in a context dependent manner 58-61.  
 
Although p53 resides constantly on its target promoters 62, 63, only the disruption of the 
interaction of p53 with its negative regulator murine double minute 2 (MDM2) causes 
p53 to be activated and thus the expression of target genes such as p21Cip1/WAF1 are 
induced 64-66. As an example, p53–MDM2 interaction is disrupted by the phosphorylation 
on p53-S15 by tumor suppressor kinase ataxia telengiectasia mutated (ATM) when DNA-
damage occurs 67, 68. Studies on p53 non-modifiable knock-in and upstream regulator 
mutant mice have suggested both redundancy and context specificity in p53 activation by 
post-translational modifications 9.  
 
1.4 Tumor suppressors in controlling cell cycle 
The p53 and TGFβ signaling pathways in part suppress tumorigenesis by preventing the 
progression of the cell division cycle under conditions of oncogenic stress 69 (Figure 2). 
The cell division cycle is composed of four phases: the G1-phase, during which cell 
achieves it normal size subsequent to cell division, the S-phase during which the DNA is 
replicated, the G2-phase, and the M-phase during which the DNA and organelles are 
equally divided between the daughter cells during mitosis 69. The cell cycle check points 
exist throughout the cell cycle. However, it is only during the G1-phase before the 
restriction point (R-point) that the cell is sensitive to both cell extrinsic and intrinsic 
stress signals and the cell either continues to grow or exits the cell cycle 70. Subsequent to 
Review of literature 
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passing the R-point cell division occurs with a similar speed regardless of whether the 
cells are normal or tumor cells. The difference being that the tumor cells pass the 
restriction point under conditions in which the normal cells would not 70. Decisive factors 
for passing the R-point are the increased activities of G1- and S-phase CDKs (CDK4, 
CDK6, CDK2) that are the ultimate targets of positive and negative cell division signals. 
In the event of a prolonged repression of CDK activity cells will not pass the R-point and 
will exit the cell cycle (to the G0 phase) by entering quiescence, senescence or terminal 
differentiation 71. 
 
CDK4/6 and CDK2 are partly activated by increased levels of cyclins, whereas CDK 
inhibitors, such as p15Ink4b, p16Ink4a, p21Cip1/WAF1, p27Kip1 of p57Kip2, inhibit CDK activity 
69. Mitogenic signals activate CDK4/6 and CDK2 by increasing cyclin D and cyclin A/E 
levels, respectively. They also activate CDK4/6 and CDK2 by downregulating CDK 
inhibitors partly via the RAS activated proto-oncogenes v-myc myelocytomatosis viral 
oncogene homolog (c-MYC) and PKB 43-46, 72-82 (Figure 2). The increase in CDK 4/6 
activity leads to the phosphorylation of the transcriptional repressor tumor suppressor 
retino blastoma proten (pRB) 83. Phosphorylation of pRB releases the repression of E2F1-
3 TFs and their transcriptional targets including cyclin E and E2Fs 83. This event 
subsequently leads to enhanced CDK2 activity and also to the hyperphosphorylation of 
pRB, which thus creates a positive feedback loop 83. The CDK inhibitors p15Ink4b and 
p21Cip1/WAF1 are partly induced by external cues that are mediated by TGFβ tumor 
suppressive signaling pathway 84-88, whereas the internal stress sensing pathways that 
include ATM- p53 DNA damage signaling induces p21Cip1/WAF1 expression 68, 89 (Figure 
2). Increased CDK inhibitor expression reduces CDK activity and pRB phosphorylation, 
which prevents the cell cycle from passing the R-point 69, 70. Mutations of CDK inhibitors 
and other tumor suppressors essential for G1/S check points are frequent in tumors 
(http://www.sanger.ac.uk/genetics/ CGP/Census/) and lead to premature cell divisions, 
which cause genomic aberrations. These, in turn, lead to further activation of oncogenes 
and inactivation of tumor suppressors 69. 
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Figure 2: Central role of p21 as an integration hub of signals from proto-oncogenes and 
tumor suppressors.  
CDK2 inhibitor p21 Cip1/WAF1 expression is positively regulated at the transcriptional level by TGFβ 
signaling and by p53. However  p21 Cip1/WAF1 expression is negatively regulated by growth factor 
induced inactivation of FoxO by PKB. In addition, PKB directly phosphorylates p21 Cip1/WAF1 which 
thus affects the stability and localization of p21 Cip1/WAF1 and prevents p21 Cip1/WAF1 binding to 
CDK2/cyclin complex. Active CDKs phosphorylate pRB, which leads to increased CDK activity via 
a positive feedback loop and eventually passing of the R-point of the cell cycle. See text for 
references and details on other components of the cell cycle machinery.
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2. Alterations in TGFβ signaling and actin cytoskeleton dynamics are 
frequent in epithelial tumor cells and stromal cells of tumor 
microenvironments 
2.1 Tumor suppression by the stroma 
Although cancer causing mutations mostly occur in tumor cells, tumor growth is largely 
regulated by the surrounding stroma. The stroma is composed of, inter alia, immune cells 
and SMC lineage cells (fibroblasts, myofibroblasts, SMC), which together with the 
epithelial cells secrete collagens, elastins, laminins, fibronectins, heparan-sulphate 
proteoglycans and nidogens to form a meshwork of the extra cellular matrix (ECM) and 
basal lamina 1, 90 (Figure 3). Attachment of epithelial cells to the basal lamina by integrins 
induces polarization of epithelial cells 91. Proper polarization, in turn, has been suggested 
to prevent induction of cell proliferation in response to oncogenic activity 92, 93. 
Supporting the notion of a crucial role played by stromal cells in the production of the 
basal lamina, the tumor suppressive activity of myoepithelial cells in cell culture has been 
associated with the expression of laminin-111, a constituent of the basal lamina 94. The 
GFs secreted by the epithelial and stromal cells can be stored within the ECM from which 
they can be liberated 95. For example, secreted TGFβ is anchored to ECM by its 
interaction with latency-associated proteins (LAPs), which in turn interact with latent-
TGFβ-binding protein (LTBP) 96. TGFβ is liberated from the complex by proteolytic 
processing of LTBP and/or LAP by matrix metalloproteinases (MMP) or plasmin 97-99. In 
addition, LAP-TGFβ interaction may be disrupted due to a conformational change in 
LAP molecule in response to mechanical traction that is conveyed from contracting cell 
to LAP by integrins 96, 100, 101. Liberated TGFβ and other GFs affect the proliferation of 
adjacent epithelial cells 1, 95 (Figure 3). 
  
Recently, the contribution of the stromal cells as an active participant in epithelial 
tumorigenesis has been highlighted by the identification of stromal mutations. Initially 
loss-of-heterozygocity (LOH) of multiple genetic loci was indicated in the stroma of 
breast ductal carcinomas in situ 102. Subsequently, p53 and PTEN mutations have also 
been identified in breast cancer tumor stroma 103, 104. Furthermore, it has been suggested 
that the inactivation of the TGFβ signaling component, Smad4, in the stroma drives GI 
polyposis of juvenile polyposis syndrome patients 105. However, this suggestion is 
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controversial and counter arguments have been put forward 106. Accordingly, the lack of 
TGFβ type II receptor (TgfβrII) in the fibroblast-specific protein 1 (Fsp1) expressing cells 
led to the increased proliferation of fibroblasts in abnormally developed ductal units in 
murine breast tissue 107, highly aggressive squamous cell carcinomas in the GI-tract and 
intraepithelial neoplasia in the prostate 108. 
 
2.2 Epithelial TGFβ signaling mediates non-cell-autonomous tumor suppression 
The TGFβ that is produced and activated by the stroma and the epithelia inhibits the 
proliferation of normal epithelial cells via the induction of cell cycle inhibitors p15Ink4b 
and p21Cip1/WAF1 84, 86-88. Accordingly, the inactivating epithelial mutations of TGFβ 
receptors have been found in hereditary and sporadic colon cancers 109-113. Moreover, 
alterations in TGFβ downstream pathways have been reported to occur frequently in 
invasive colorectal cancers 114.  
 
TGFβ binding to TGFβ receptors (TGFβRI and TGFβRII) activates several downstream 
pathways, of which Smad (SMA and MAD related protein) signaling pathway has been 
especially indicated in growth suppression 115 (Figure 3). Activated TGFβRI 
phosphorylates and activates receptor Smads (R-Smad: Smad2 and Smad3), which 
consequently bind Smad4 (co-Smad) and accumulate within the nucleus possibly because 
of inhibited nuclear export 115, 116. Nuclear Smad complex binds DNA with low affinity 
and thus interactions with other transcription factors are needed 117. Co-factors of Smads, 
including FoxO, induce Smad mediated activation of target gene transcription, which 
includes the cell cycle inhibitors p15Ink4b and p21Cip1/WAF1 118, 119. The crucial role of 
TGFβ signaling in growth control is highlighted by the existence of complex feedback 
loops. Positive feedback loops include the auto induction of the TGFβ gene 120-123, 
whereas the negative feedback loops include the induction of the inhibitory Smad, 
denoted Smad7, which attenuates the TGFβ signaling at several levels (Figure 3) 124.  
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Figure 3: Epithelia-stroma microenvironment and TGFβ signaling  
A Stromal cells (brown) affect epithelial proliferation and polarization by secreating and activating 
growth factors, such as TGFβ, and by contributing to components of basal lamina and ECM. B 
TGFβ signal transduction pathway with its feedback loops leads to the controlled expression of 
cell cycle inhibitors p21Cip1/WAF1 and p15Ink4b. See text for references.  
2.3 Altered actomyosin fiber dynamics in stromal and epithelial cells of tumors are 
regulated by RhoA signaling  
In addition to regulating CDK inhibitor expression TGFβ affects tumorigenesis by 
inducing actin cytoskeleton contractility in epithelial and stromal cells 1, 125. TGFβ 
induced contractility may induce adverse effects in tumorigenic epithelial cells by 
contributing to the epithelial-mesenchymal transition (EMT). This is characterized by the 
acquisition of mesenchymal characteristics: disruption of epithelial cell-cell junctions, 
increase in ECM component production and increase in cell motility 125-127. On the other 
hand, TGFβ induced cell contraction in stromal cells leads to the modification of ECM 
and subsequent GF activation 1. Thus contraction of stromal cells, in turn, affect the 
proliferation of adjacent epithelial cells (see 2.1) 1.  
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TGFβ induces mesenchymal characteristics and contractility by driving the expression of 
actomyosin fibers, such as actin stress fibers 125, 128. Actin stress fiber formation is 
initiated from within focal adhesions, which is followed by the incorporation of myosin 
units 129, 130. Stress fibers from the opposing poles of the cell converge and form 
contractile ventral stress fiber bundles. These bundles consist of several actin filaments of 
alternating polarity, intercalating myosin units, alpha actinins that cross link the stress 
fibers and tropomyosins 129, 130. Myosin units use ATP as an energy source to induce the 
contraction of the ventral stress fiber bundles. The resulting contraction is mediated by 
the sliding over of antiparallel actin filaments  131. Contraction of the stress fiber bundle is 
causative for cell contraction, force transmission to ECM and thus tension between these 
two due to the tethering of stress fibers to focal adhesions 131.  
 
Cell contractility and TGFβ are essential for SMC lineage differentiation. Thick 
contractile actin stress fiber bundles define proto-myofibroblasts that are found in the 
granulation tissue of healing wounds 132. Increased tension upon contractility together 
with TGFβ induces myofibroblast differentiation that is characterized by a-smooth 
muscle actin (α-SMA) expression and its subsequent incorporation into the stress fibers 1, 
132. Cells with α -SMA positive stress fibers have increased force production that leads to 
increased integrin mediated activation of TGFβ (see 2.1) 100, 101, 133. Thus there is a 
positive feedback loop between contractility and TGFβ activation. Concomitant with the 
stress fiber strengthening, focal adhesions mature and enlarge 134-136. In addition to 
regulating actin stress fibers TGFβ has also been indicated in the formation of non-
contractile actin filament structures such as lamellopodias 137, 138. 
 
RhoA GTPase is a key regulator of actin stress fiber contractility and thus it is not 
surprising that the regulation of RhoA in response to TGFβ has been suggested to be 
essential for TGFβ induced EMT 137, 139. RhoA is predominantly active in the tail ends of 
migrating cells 140, 141. In this location, RhoA possibly induces the contraction and 
dissociation of posterior focal adhesions 142, 143. Accordingly, ventral actin stress fibers 
have been found to locate mostly in the rear of motile cells 144. Recently, it was proposed 
that motile tumor cells could switch between adhesion dependent to adhesion 
independent (amoeboid) types of motility, similar to that observed in leukocytes 145. 
Moreover, ameboid-type motility requires RhoA signaling for the induction of cortical 
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actomyosin contractility 146. The activation of RhoA signaling has been associated with 
tumorigenesis that is consistent with the central role of RhoA in modulating contractility 
in epithelial and stromal cells  147. 
 
RhoA regulates stress fiber contraction via a complex network of protein interactions. 
The key role downstream of RhoA is played by phosphorylation status of the myosin 
light chain (MLC), which induces ATPase activity of myosin 2 and leads to contraction 
148. In non-muscle cells RhoA signaling induces MLC phosphorylation mostly via the 
activation of Rho kinase (ROCK) 149. Negative regulation of phosphorylated MLC is 
exerted by myosin light chain phosphatase (MLCP), which is composed of catalytic 
protein phosphatase 1 (PP1), myosin phosphatase targeting 1 (MYPT1) and small 20kDa 
subunit 150-152. Negative regulation by MLCP can be blocked by RhoA via the induction 
of MYPT phosphorylation at several sites by ROCK or other kinases, which leads to the 
inhibition and/or sequestration of the phosphatase complex 153-157. Alternatively, ROCK 
could inhibit MLCP via the phosphorylation of protein phosphatase 1 regulatory subunit 
14A (CPI-17) 158, 159.  
 
3. LKB1 as a tumor suppressor 
3.1 Inherited mutations of LKB1 are causative for gastrointestinal polyposis 
The search for the causative mutations of Peutz-Jeghers syndrome (PJS) identified serine 
threonine kinase LKB1 (also known as STK11) in 1998 4, 5. The most severe manifestation 
of PJS is gastrointestinal (GI) polyposis. Its onset occurs during the second or third 
decade of life and is diagnosed by abdominal pain, bleeding or endoscopy/colonoscopy 
160. Benign polyps arise throughout the GI-tract, are pedunculated in shape and classified 
as hamartomas 160. Polyps contain most of the differentiated cell types found in the 
adjacent normal tissue 160. Juvenile polyposis syndrome, instead, is caused by mutations 
in SMAD4 or in bone morphogenic protein receptor 1 (BMPR1)  and Cowden syndrome 
is caused by mutations in PTEN. Both conditions are characterized by hamartomatous 
polyps in the GI-tract 161 162. When polyps of these different hamartoma syndromes are 
compared PJS polyps are found to have the most predominant stromal stalk. 160, 163. 
Consistently, the PJS polyps also have the highest occupancy of SMC-lineage cells 160, 
163. 
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Recent reports indicate LKB1 mutations in up to 94% of PJS patients 164-168, which 
suggests that all the PJS patients are LKB1 deficient. Causality between the LKB1 
mutations and PJS is indicated by the analysis of Lkb1 deficient mice. Lkb1 heterozygose 
mice survive and develop remarkably similar polyps to those found in PJS patients. The 
polyps predominately locate within the pyloric region and to a lesser extent elsewhere in 
the stomach. They can also occur in the intestine though this is comparatively rare. 
Polyps begin to appear at the age of 5 months and cause the death of the mice at the age 
of 8 months and onwards 169-172. In contrast, analysis of nullizygous mice demonstrated 
embryonic lethality between days E8.5-E9.5 173. This was possibly because of vascular 
defects and indicates an essential role for LKB1 during embryo development 173. 
 
In addition to polyposis, epidemiological studies suggest that PJS patients have an 
increased risk of cancers of the GI-tract, gynecological cancers, and also breast cancer 174, 
175. PJS patients have between a 41 to 60% risk of developing a first cancer before the age 
of 60, compared to only 8.5%, for the general population, which indicates a 5-7 fold 
increase in cancer risk at 60 174, 175.  
 
3.2 LKB1 mutations in sporadic cancers 
The status of LKB1 as a tumor suppressor has been highlighted by recent reports that 
demonstrate frequent LKB1 mutations in sporadic tumors. In contrast to tumor spectrum 
of PJS patients, sporadic mutations of LKB1 were identified in up to 20% of cervical 
cancers 176, 177 and up to 34% of non-small cell lung carcinomas (NSCLC) 6, 7, 176, 178-180. 
In NSCLC, LKB1 mutations are the most frequent in adenocarcinomas but are also found 
in squamous cell carcinomas and in large cell carcinomas 6, 179, 181, 182. Kinome and 
genome wide mutation analyses of diverse tumor samples have consolidated the notion of 
tissue specificity in tumor suppression by LKB1. Screenings confirmed LKB1 mutations 
in NSCLC 51, 181, 183, 184 but did not find significant numbers of LKB1 mutations in other 
types of tumors 181, 184-189. The tissue specificity of LKB1 in tumor suppression is in 
contrast to its ubiquitous expression pattern 190 and could reflect differential expression of 
LKB1 substrates and/or differental function of LKB1 in various tissues. Consistent with 
tissue specific tumorigenesis upon LKB1 mutations, accumulation of mutations in tumor 
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type specific signaling pathways have been reported 191. For example, mutations of the 
BMP pathway are frequent in tumors of GI-tract but more rare in other tumor types 191.  
 
Analysis of those mutations that co-segregate or are mutually exclusive with the LKB1 
mutations could reveal signaling pathways essential for tumor suppression by LKB1. 
Interestingly, studies on lung adenocarcinomas indicate mutual exclusiveness between 
EGFR activating and LKB1 inactivating mutations 51, 179. In contrast, activating mutations 
of KRAS, a downstream target of EGFR, co-segregate with LKB1 inactivating mutations 
179. These observations suggest that one of the following occurs: 1) LKB1 is involved in 
EGFR signaling but is part of an EGFR downstream pathway other than KRAS, 2) LKB1 
mutations sensitize cells to oncogenic stress by EGFR, or 3) LKB1 and EGFR mutated 
lung adenocarcinomas represent separate sub-types that can not be distinguished from 
each other with current methods. 
 
3.3 LKB1 mutations promote both initiation and progression in tumorigenesis 
Studies on tumors associated with LKB1 mutations have implicated that a loss of LKB1 
promotes both tumor initiation and aggressiveness. The former is supported by the benign 
nature of PJS polyps together with an increased number of tumors upon Lkb1 inactivation 
in the lung adenocarcinomas of mice expressing oncogenic Kras 6. Moreover, LKB1 
mutation frequency did not correlate with the clinical stage of NSCLC patients, which 
indicated that LKB1 mutations occur early on in tumor development 179. However, LKB1 
mutations were associated with the shorter survival of lung adenocarcinoma patients, 
although the sample size was not enough to ensure statistical significance 179. 
Consistently, Lkb1 inactivation together with Kras activation induced lung 
adenocarcinoma metastasis, whereas Kras mutation alone was not sufficient for induction 
of metastasis or local invasions 6. Furthermore, cervical cancer LKB1 mutations were 
reported to associate with poor prognosis 177. The mechanisms of the underlying 
increased tumor aggressiveness enhanced by LKB1 mutations are not known but obvious 
candidates include the induction of EMT and/or changes in cell cytoskeleton upon the 
loss of LKB1.  
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4. Regulation of LKB1 kinase activity and downstream signaling 
4.1 LKB1 kinase complex 
LKB1 gene encodes a serine/threonine kinase of 433 amino acids (aa) 4, 5, 192. The 
integrity of the LKB1 kinase domain and kinase activity are crucial for the tumor 
suppressive function of LKB1 as almost all missense, nonsense or frameshift mutations 
of LKB1 in tumors have been demonstrated or predicted to interfere with the kinase 
function 51, 192, 193. LKB1 forms a kinase complex with pseudokinase Ste20 related 
adaptor (STRADα and STRADβ) 194, 195 and the scaffolding protein MO25 (MO25α and 
MO25β; also known as calcium-binding protein 39) 196. Upon interaction between 
STRAD and MO25, STRAD binds to ATP and shifts to the closed “active” conformation 
197, which promotes the complex formation with LKB1 and a conformational change of 
the LKB1 activation loop 198. Kinase complex formation induces LKB1 kinase activity in 
vitro and also in cell culture and it has been suggested to be essential for LKB1 signaling 
194, 196, 199. 
 
4.2 Regulation of LKB1 activity 
How LKB1 activity is regulated is still largely uncharacterized to date. Currently, the 
focus of investigations is on the post-translational modifications of LKB1. LKB1 is not 
regulated by T-loop phosphorylation 193, which is the classic mechanism of regulating 
kinase activity 200. Moreover, there are no reports about regulation of expression levels of 
LKB1 or its kinase complex partners. However, LKB1 has been reported to be covalently 
modified by phosphorylation of several residues in cells 201-206 in addition to farnesylation 
203, 207 and acetylation 208. Phosphorylation of LKB1-T363 is exerted by the ATM tumor 
suppressor kinase in response to DNA damage 202 and has been implicated in LKB1 
mediated cell cycle arrest in B-cells that are undergoing immunoglobulin gene 
remodeling 209. LKB1-S428, in turn, has been suggested to be a direct target of protein 
kinase A (PKA) 203, 207, p90 ribosomal S6 kinase (p90RSK) 203 and atypical protein kinase 
C (aPKC) 210, Its phosphorylation has been suggested to contribute to the regulation of 
epithelial 211 and neuronal polarity by LKB1 212-214. In contrast to these studies, 
phosphorylation of LKB1-S428 by p90RSK was reported to inhibit LKB1 signaling 
activity in SK-MEL-28 cells when coinciding with phosphorylation of LKB1-S325 by 
extracellular signal-regulated kinase (ERK, see 5.1) 215. Regulation of LKB1 function by 
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phosphorylation could take place at the level of LKB1-substrate complex formation as in 
vitro kinase activity was not affected upon inhibition of upstream kinases or mutagenesis 
of phosphorylated residues 201-203. 
 
As to whether the phosphorylation of LKB1 at T363 or at S428 is critical for LKB1 
mediated tumor suppression is still an open question. Mutations of PKA, aPKC or p90RSK 
have not been identified in lung adenocarcinomas 51, 181, 184 or in PJS, which could be due 
to a possible redundancy in phosphorylation of LKB1-S428. Interestingly, mutations of 
ATM can be found in lung adenocarcinomas although this is rarer than for LKB1 
mutations 51. Co-segregation studies of ATM and LKB1 in lung adenocarcinomas or the 
creation of LKB1-T363A knock–in mice could provide an answer as to the relevance of a 
direct link between these two tumor suppressors. 
 
Alternatively, the LKB1 signaling activity could be regulated spatially via changes in 
LKB1 localization in a similar manner to the tumor suppressors p53 and Smad4 216-218. 
Various patterns of LKB1 localization have been observed: Caenorhabditis elegans 
homologue of LKB1 (PAR-4) localized at cell cortex and in the cytoplasm 219, in 
Drosophila melanogaster LKB1 localized at the cell membrane and in the cytoplasm 211, 
Xenopus laevis homologue Xeek1 was reported to localize exclusively in the cytoplasm 
220, mouse Lkb1 was predominantly nuclear although modest amounts were also found in 
the cytoplasm and membranes 203, 221 and, finally, human LKB1 has been reported to 
localize into both the nucleus and the cytoplasm 222. The context dependent LKB1 
localization and the ability of co-expressed Lkb1 interacting protein 1 (Lip1) to induce 
cytoplasmic re-localization of Lkb1 223 support the idea of the dynamic regulation of 
LKB1 localization and encourage further studies on regulation of LKB1 localization and 
its significance on LKB1 function. 
 
4.3 LKB1 activates 14 substrate kinases indicated in the regulation of metabolism 
and polarity 
LKB1 on its own or in the context of the kinase complex has been implicated in the 
phosphorylation of p53 203, AGS3 224, STRADα 194, p21-activated kinase-1 (PAK1) 225, 
GSK3β 226, and PTEN 227, 228. Interestingly, PTEN, whose hereditary mutations cause 
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hamartoma syndromes similar to those associated with LKB1 162, was reported to be 
activated upon phosphorylation on several residues by LKB1 228. A downstream target of 
PTEN, denoted PKB (Figure 1), was consistently inhibited upon LKB1 dependent 
activation of PTEN in endothelial cells. In contrast to these results, PKB has been found 
to be inhibited in several LKB1 deficient cell lines and primary mouse embryonic 
fibroblasts (MEF) 229, 230. Furthermore, synergistic effects of LKB1 and PTEN deletion on 
bladder tumorigenesis in mice 231 indicates that in some tissues and cell types these tumor 
suppressors are part of distinct signaling pathways.  
 
Identification of AMP-activated kinase (AMPKα1 and AMPKα2) as LKB1 substrate 232, 
233 proved to be extremely significant for LKB1 research as it paved the road for a 
subsequent study that indicated LKB1 in the phosphorylation of 12 kinases closely 
related to AMPK 199 (figure 4). Phosphorylation of the T-loop threonine of AMPKα1-2, 
brain-specific kinase 1-2 (BRSK1-2, also known as SAD-B and SAD-A), microtubule-
affinity regulating kinase 1-4 (MARK1-4), NUAK 1-2 (also known as ARK5 and 
SNARK), salt inducible kinase 1-3 (SIK1-3, SIK2 is also known as QIK and SIK3 as 
QSK) and SNF1-related kinase (SNRK) by LKB1 induced the kinase activities in vitro 
199, 232, 234. In contrast to other reported LKB1 substrates (see previous paragraph), the 
requirement for LKB1 in the activation of most of these kinases has been indicated by 
studies in MEFs and HeLa cells that lack LKB1 199, 232, 234 in addition to tumors and 
tissues deficient in their Lkb1 expression 6, 213, 235-238. As an exception, AMPKα1 activity 
was not lost in the heart and skeletal muscle in the absence of Lkb1 239, 240. This was 
probably due to the homologous role played by calcium/calmodulin-dependent protein 
kinase kinase β (CamKKβ) in respect of the T-loop kinase of AMPK 241, 242. Accordingly, 
CamKKβ has been shown to activate only AMPKα1 and AMPKα2 of all 14 AMPK-
related kinases in vitro and in cell culture 243. The ability of MARK activating kinase 
(MARKK) to interact with MARK1-4 in cells and to activate MARK1-4 in vitro 244 
suggests that in some specific conditions kinases other than LKB1 or CamKKβ might be 
involved in the activation of LKB1 substrate kinases. 
 
Identification of the LKB1 substrate kinases has linked LKB1 kinase activity to several 
cellular functions (Figure 4). The best characterized LKB1 substrate kinase is AMPK, 
whose activation is a two-step process in which both the phosphorylation of the T-loop 
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by LKB1 and the AMP binding by AMPK γ-subunit are crucial for robust kinase activity 
245, 246. AMPK was initially identified as an upstream kinase and inhibitor of 3-hydroxy-3-
methylglutaryl-CoA reductase (HMGR) and acetyl co-enzyme A (ACC) 247, 248, which are 
essential respective enzymes in cholesterol and lipid synthesis pathways. Based on the 
sequence around these phosphorylation sites and in vitro peptide library screening the 
AMPK consensus target sequence was proposed 249, 250. The consensus sequence contains 
the following positions in relation to the target serine: a basic residue on the aa -3 or -4, a 
hydrophobic bulky aa at position -5 and +4 and preference for polar aa at +3, all of which 
make AMPK a higly selective kinase 249, 250. The establishment of AMPK consensus 
sequence has facilitated identification of several AMPK targets 251 one of which was 
tumor suppressor TSC2 252. Most of the AMPK substrates are linked to the regulation of 
metabolism similar to that of AMPK homologue sucrose non-fermenting 1 (SNF1) in 
Saccharomyces cerevisiae 253. In addition to AMPK, SIK1 and SIK2 have been indicated 
in metabolic regulation 254. SIK1 and SIK2 inhibit the expression of genes involved in 
gluconeogenesis via phosphorylation and subsequent sequestration of cAMP response 
element-binding protein (CREB)-regulated transcription coactivator 2 (CRTC2) 254. 
SIK1-2 phosphorylates CRTC2 in response to hormonal signals, whereas AMPK has 
been indicated in the phosphorylation of the same residues of CRTC2 in response to 
energetic stress 255. The regulation of metabolism and thus cell growth by AMPK and 
SIK1-2 brings them forth as as candidate mediators of LKB1 tumor suppression as tumor 
cells are forced to reprogram their metabolism to survive under conditions of low oxygen 
and constant need of building blocks 256. Instead of regulation of metabolism, MARK1-4 
and BRSK1-2 have been indicated in the phosphorylation of microtubule-associated 
proteins (MAPs) 257, 258, which normally bind to and stabilize microtubules (MT) but 
upon phosphorylation by MARK1-4 or BRSK1-2 detach, which leads to MT 
destabilization 257. NUAK1-2, SIK3, and SNRK are poorly characterized. Induction of 
NUAK2 activity in response to energetic stress and ultraviolet radiation associates 
NUAK2 with molecular mechanisms involved in tumorigenesis 259-261. 
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Figure 4: LKB1 signaling network.  
LKB1 kinase complex (modified from 198) phosphorylates LKB1 substrate kinases and is modified 
by phosphorylation by ATM, PKA, pRSK90, and possibly by ERK. This schematic figure is 
modified from 262. See text for references.  
Paucity of knowledge on LKB1 substrate kinases together with their ability to 
phosphorylate common targets in vitro 199 and ability of AMPK and SIKs to induce 
CRTC2 phosphorylation in vivo 255 (Figure 4) has raised the hypothesis of there being 
some redundancy of LKB1 downstream signaling pathways 263. However, the differential 
preferences on in vitro substrates 199 and the inducibility of SIK1 264, AMPKα2 265, 
NUAK1 266 and NUAK2 260 expression levels in response to conditions specific for each 
of the kinases imply that LKB1 substrate kinases are not redundant in vivo. Indeed, 
embryonic lethality of BRSK1-/-;BRSK2-/- 258, AMPKα1-/-;AMPKα2-/- 267, and MARK2-/-
;MARK3-/- 268 double knock out mice in addition to increased plasma glucose levels in 
AMPKα2-/- mice 269 and other phenotypes of mice harboring deletion of single LKB1 
substrate kinase gene 269-276,support the hypothesis of unique functions of LKB1 substrate 
kinases. These indications of non-redundant functions allow genetic and cell biological 
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studies in addressing, which of the 14 substrate kinases mediate the LKB1 tumor 
suppression in different situations. 
 
5. Suggested tumor suppressive functions of LKB1 
Cell culture and in vivo studies have demonsrated associations between LKB1 and 
several cellular functions. Involvement of LKB1 in regulation of cell proliferation, 
metabolism, polarity, and cytoskeleton are potentially relevant for tumor suppression by 
LKB1 as these cellular processes are commonly deregulated in tumors 256, 277.  
 
5.1 LKB1 is indicated in the suppression of cell proliferation 
Cell culture experiments by several laboratories have provided evidence for the 
involvement of LKB1 in the suppression of cell proliferation. In primary MEFs Lkb1 
deletion was suggested to abrogate culture-induced senescence and led to the 
immortalization of the cells 169 whereas the overexpression of LKB1 has been 
demonstrated to restrict the growth of several cancer cell lines 278-280. The re-introduction 
of LKB1 expression in the G361 melanoma cell line 280, A549 lung adenocarcinoma cell 
line 278 and MDA-MB-435 breast cancer cell line 279 suppressed cell proliferation, which 
was possibly due to arrest of the cell cycle at the G1 stage 280. Whether LKB1 affects cell 
proliferation directly by regulating CDK activity (see 1.4), or indirectly through the 
regulation of metabolism or polarity merits further investigation. Nevertheless, cell cycle 
phenotype in response to the manipulation of LKB1 levels indicate LKB1 as being a 
gatekeeper of cell division and thus provides a platform for more detailed studies of 
LKB1 downstream signaling in the suppression of cell proliferation. 
 
Phosphorylation of LKB1-S325 and LKB1-S428 by ERK and p90RSK, respectively, were 
suggested to prevent the suppression of proliferation of SK-MEL-28 melanoma cells by 
LKB1 215. In this context ERK and p90RSK activities were induced by B-RAF-V600E 
oncogenic mutation, which are frequent in melanomas 281. The suggested link between B-
RAF and LKB1 places LKB1 downstream of EGFR signaling and could thus provide an 
explanation for the mutual exclusiveness of LKB1 inactivating and EGFR activating 
mutations and co-segregation of LKB1 inactivating and KRAS activating mutations in 
lung adenocarcinomas 6, 179 (see 3.2). In tumors B-RAF has been suggested to be 
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activated by EGFR downstream effector RAP1 282, 283 whereas RAF-1 is activated by 
RAS 23-26. Thus, mutations of LKB1 and KRAS in lung adenocarcinomas would activate 
or partly activate both RAF1 and B-RAF signaling pathways downstream of EGFR. 
However, as the re-introduction of LKB1 induces cell cycle arrest in G361 melanoma 
cells 280, which harbor the B-RAF-V600E mutation (Cosmic database, 
www.sanger.ac.uk/genetics/CGP/cosmic/), it is plausible that the inhibition of LKB1 by 
B-RAF occurs only in certain contexts or involves LKB1 downstream pathways that are 
not responsible for LKB1 induced cell cycle arrest in G361 cells. 
 
AMPK activity has also been implicated in the suppression of cell proliferation 284, 285, 
which indicates the possibility of AMPK being a potential mediator of tumor suppression 
by LKB1. Interestingly, mutations of the AMPK substrate TSC2 (Figures 1 and 4) 229, 252 
are causative for tuberous sclerosis, which is a condition that is characterized by 
hamartomatous growth of the skin, kidney, heart, and brain 286 whereas hereditary 
mutations of TSC1/2 activator PTEN lead to multiple syndromes similar to PJS, which 
are characterized by hamartomatous polyps in the GI-tract 162. Tumorigenesis upon 
TSC1/2 mutations has been suggested to be caused by the activation of the mammalian 
target of rapamycin complex 1 (mTORC1) as a treatment of tuberous sclerosis patients 
and model rats with mTORC1 inhibitor rapamycin led to the regression of tumors 287, 288. 
Intriguingly, elevated phospho-S6 levels, an indicator of mTORC1 activity (Figure 1), 
have been observed in the epithelia of PJS polyps, which is suggestive of AMPK 
attenuation 229. Moreover, several epidemiological studies on type 2 diabetes patients 
have revealed a significant decrease in the incidence of cancer and mortality among 
patients treated with metformin 289-291 an AMPK activator 292, 293, which is evidence that 
supports the tumor suppressive role of AMPK. However, the presence of LKB1 mutations 
and lack of AMPK mutations in lung adenocarcinomas 51 or PJS 262 (see 3.1 and 3.2) 
imply that LKB1 substrate kinase other than AMPK might be relevant for tumor 
suppression by LKB1 and that multiple LKB1 substrates are involved. 
 
5.2 Regulation of cell polarity and cytoskeleton by LKB1 
Initially, a role for LKB1 in cell polarity was demonstrated by studies on Caenorhabditis 
elegans in which LKB1 homologue PAR-4 was required for the asymmetry of an early 
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embryo 219, 294, 295. Subsequently, LKB1 was shown to be required for the polarity of an 
oocyte and epithelial cells in Drosophila melanogaster 211. In the eye rhabdomere of 
Drosophila melanogaster 296 and the developing mouse pancreas 238 Lkb1 deletion was 
associated with a deficiency of tight junctions (TJ) and adherence junctions (AJ). These 
findings could be indicative of a mechanism for the noted polarity defects of Drosophila 
melanogaster follicle epithelia 211 as integrity of the cell-cell junctions is a prerequisite 
for proper epithelial polarity 297. Consistently, the downregulation of LKB1 in a three-
dimensional cell culture model of MCF10A mammary epithelial cells led to the inability 
to form hollow acinar structures and was associated with deficient cell-cell junctions 93. 
Thus it is intriguing that the inactivation of the mouse mammary tissue Lkb1 led to 
tumorigenesis 298. Furthermore, PJS patients have an increased risk of breast cancer 174. 
Together with the association of LKB1 inactivation with EMT 299 and increased 
invasiveness of Lkb1 deficient lung adenocarcinomas 6 (see 3.3) these results suggest that 
the regulation of epithelial polarity contributes to tumor suppression by LKB1. More 
specifically, it has been postulated that deficient epithelial polarity drives PJS polyposis 
300, 301. 
 
Epithelial cell-cell junction formation and maintenance are interdependent on junctional 
complex formation and carefully controlled microtubule and actomyosin fiber dynamics 
305. To date studies have not yielded any evidence for the direct modification of cell 
junction components by LKB1. Therefore attention has been redirected to the regulation 
of cell cytoskeleton by LKB1. Consistently, it has been suggested that LKB1 activity 
regulates actin polarization in single colorectal cancer cells in culture 306 and 
microtubules in various cell types 307, 308, which indicates that regulation of cell 
cytoskeleton by LKB1 is not secondary to the regulation of cell-cell contacts. 
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Figure 5. LKB1 signaling in control of epithelial cell polarity 
In polarized epithelial cells TJs and AJs, whose formation and maintenance are dependent on the 
actomyosin ring, separate basolateral (bottom) and apical (top) domains. In intestinal epithelial 
cells integrins and the nucleus are located in the basolateral domain, whereas the actin brush 
border and microvilli are located in the apical domain. Microtubules originate in the centrosome 
and traffic vesicles from the golgi to the apical or to the basolateral domain. LKB1 substrate 
kinase AMPK has been been implicated in the regulation of actin cytoskeleton and microtubules 
whereas MARKs have been shown to regulate microtubule stability, cell-cell junctions and apico-
basal polarity 302. Potentially relevant for epithelial polarity are also BRSK1 and SIK2, which 
regulate centrosome duplication 303 and separation 304, respectively. However, these have only 
been studied in non-polarized cell types 303, 304. See text for references. 
LKB1 substrate kinases have been indicated in the direct phosphorylation of cytoskeletal 
components, which could provide a mechanism for the cytoskeleton and cell-cell junction 
regulation by LKB1. It has been suggested that MARK1-4 and BRSK1-2 destabilize 
microtubules by phosphorylating the microtubule associated proteins (MAP) 213, 257, 258, 308 
whereas AMPK has been reported to stabilize microtubules by phosphorylating 
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cytoplasmic linker protein 170 (CLIP-170) 309. Moreover, AMPK has been suggested to 
directly modulate actomyosin fiber dynamics by phosphorylating MLC 310. The ability of 
MLC mutant, which mimics the phosphorylated state, to rescue the epithelial polarity 
defects of AMPK mutant Drosophila and to mimic the activation of LKB1 on the 
polarization of actin cytoskeleton in LS174T-W4 colorectal cancer cells 310 suggests a 
mediator role for AMPK in the cell cytoskeletal regulation by LKB1. Consistently, 
constitutively active AMPK mutant was able to rescue the epithelial polarity defects of 
LKB1 deleted Drosophila. Another LKB1 substrate implicated in the regulation of actin 
dynamics is NUAK2. The overexpression of NUAK2 in HEPG2 induced cell detachment 
and disruption of actin fibers in glucose starved cells 261. Therefore, it appears likely that 
LKB1 also regulates actin cytoskeleton in mammalian cells as based on the studies 
presented above. Nonetheless, further studies are required to establish detailed molecular 
mechanisms of the regulation of the actin cytoskeleton by mammalian LKB1 and their 
possible relevance for tumor suppression by LKB1.   
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AIMS OF THE STUDY 
Prior to writing this thesis the first cell culture model of LKB1 induced cell cycle arrest 
had been established 280 and polyposis prone Lkb1+/- mice were created in the laboratory. 
Analysis of Lkb1+/- mice revealed development of remarkably similar polyps to those in 
PJS patients characterized by prominent stalk composed of SMC lineage cells 172. Based 
on these tools the aims were set as follows:  
 
1. Identification of the molecular mechanism that contributes to LKB1 tumor suppressive 
function by studying LKB1 induced cell cycle arrest in G361 melanoma cells and the 
regulation of LKB1 localization in other cell lines (publication I). 
 
2. Characterization of potential tumor suppressive LKB1 functions and LKB1 signaling 
pathways in SMC lineage cells by deleting Lkb1 in the SM22 positive cell in vivo and in 
cell culture (publication II and III).  
 
3. The studies on the 2nd aim identified Lkb1 as a regulator of actin stress fibers (publication 
III). The third aim was to investigate whether the interaction between the LKB1 substrate 
kinase NUAK2 and an actin binding protein MRIP, which was found in the yeast two 
hybrid screen carried out in the laboratory, would play a role in the regulation of actin 
stress fibers (publication IV). 
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MATERIALS AND METHODS 
DNA constructs (unpublished data) 
Amino-terminally (N-terminally) tagged GST-STRADα was constructed by recombining 
the STRADα insert from pDONR221-STRADα with the pDEST27 vector via a LR-
recombination reaction according to manufacturers protocol (Invitrogen). Enhanced green 
fluorescent protein (EGFP) tagged wild type LKB1, EGFP-LKB1-G163D, EGFP-LKB1-
KD and EGFP-LKB1-D176N were subcloned by EcoRI-SalI digestion of pAHC-LKB1 
192, pAHC -LKB1-G163D 192, pAHC-LKB1-KD (publication I) and pAHC-LKB1-
D176N (publication I) vectors and subsequent ligation of extracted LKB1 inserts to 
EcoRI-SalI cut pEGFP vector. 
 
GST-pulldown (unpublished data) 
293 embryonic kidney cells were transfected with pDEST27-STRADα (GST-STRADα), 
pAHC-MO25α (HA-MO25α) and pEGFP-LKB1, pEGFP-LKB1-G163D, pEGFP-LKB1-
KD, pEGFP-LKB1-D176N, pAHC-LKB1, pAHC-LKB1-SL26 or pAHC-LKB1-SL8 
using Fugene (Roche) according to the manufacturer’s instructions. Subsequently, at 48 
hours after transfection the cells were washed once with room temperature phosphate 
buffered (pH 7.4) isotonic saline (PBS), placed on ice, and washed once with ice cold 
PBS followed by lysis in buffer C containing 50mM Tris pH7.5, 1mM EGTA, 1mM 
EDTA, 1% triton, 0.27 M sucrose and cocktail of protease and phosphatase inhibitors. 
Subsequent to centrifugation at 20 800 g for 10 minutes 500 ug of protein lysate was first 
incubated with gluthatione-sepharose beads (Amersham) under rotation at +4 celsius 
degrees for 1 hour and then washed 10 times with ice cold buffer C. Western blotting 
analysis was carried out as described in publication I of this thesis with the exception that 
the antibodies used were specific for LKB1 (Upstate Biotechnologies), HA (12CA5, 
Babco), and GST (Genescript). 
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Methods, antibodies, cells, siRNA oligos, plasmids and mouse strains used in 
publications (I-IV) 
The materials and methods used in publications I-IV of this study are tabulated below, 
and described in detail in the original publications, which are referred to here by their 
roman numerals. 
 
Table 1. Methods used in this study 
method used in applied by the author in 
adenoviral infection II, III II, III 
adenovirus production II, III II, III 
cell culture I, II, III, IV I, II, III, IV 
cell fractionation I I 
contractility assay III III 
expression vector transfection I, III, IV I, III, IV 
flow cytometry analysis I I* 
GST-pulldown IV, U U 
image analysis II, IV IV 
immunofluorescence analysis (IF) I, III, IV I, III, IV 
immunohistochemistry analysis (IHC) II   
immunoprecipitation analysis (IP) I, III, IV I, III 
in vitro kinase assay I I 
luciferase assay I, III III 
macroscopic assessment of polyps II   
microscopy I, II, III, IV I, II, III, IV 
mouse breeding II, III III 
mutagenesis of plasmid constructs I, IV I 
PAIL-assay II II 
plasmid DNA preparations I, III, IV I, III 
prepping of primary MEFs II, III II, III 
quantitative PCR II, III, IV IV 
recombination measurement II   
RNA extraction II, III, IV IV 
siRNA transfection III, IV III, IV 
statistical analysis I, II, III, IV II, III, IV 
sub-cloning of expression vectors I, IV, U I, U 
tamoxifen injections II   
western blotting analysis (WB) I, II, III, IV I, II, III, IV 
*= author contributed to flow cytometry analysis  
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Table 2. Primary antibodies used in this study 
name, clone description, use reference 
used in 
study 
α -14-3-3b, K-19-
G rabbit polyclonal ab, WB Santa Cruz Biotechnology inc. I 
α -actin, AC-40 mouse monoclonal ab, WB Sigma III 
α -AMPKa rabbit polyclonal ab, WB Cell signaling III 
α -CDK7, C-4 mouse monoclonal ab, WB Santa Cruz Biotechnology inc. III 
α -CDK7, MO15 mouse monoclonal ab, WB Zymed laboratories I 
α -cyclin B1, 
GNS-1 mouse monoclonal ab, IF Santa Cruz Biotechnology inc. I 
α -desmin, DE-R-
11 mouse monoclonal ab, IHC Novocastra II 
α -FAK, 77/FAK mouse monoclonal ab, IP BD Transduction laboratories III 
α -GFP, TP401 rabbit polyclonal ab, WB Torrey Pines Biolabs IV 
α -GST, ab9085 rabbit polyclonal ab, IF Abcam IV 
α -GST, AP308P mouse monoclonal, WB Chemicon International IV 
α -HA, 12CA5 
mouse monoclonal ab, 
WB/IF/IP Babco I, IV 
α -Ki-67, M7249 rat monoclonal ab, IHC Dako  II 
α -LKB1 rabbit polyclonal ab, WB/IP 272 I 
α -LKB1 Sheep polyclonal ab, WB Upstate Biotechnologies I 
α -LKB1, 
Ley37D-G6 mouse monoclonal ab, WB Abcam III 
α -MLC, M4401 mouse monoclonal ab, WB Sigma IV 
α -MRTFA, C-19 goat polyclonal, IF Santa Cruz Biotechnology inc. III 
α -MYC, 9E10 mouse monoclonal ab, IP Babco I 
α -Mypt1 2634 rabbit polyclonal ab, WB Cell signaling technology IV 
α -p21, C19 rabbit polyclonal ab, IF Santa Cruz Biotechnology inc. I 
α -p27, F8 mouse monoclonal ab, WB Santa Cruz Biotechnology inc. I 
α -phospho-ACC, 
3661 rabbit polyclonal ab, IHC Cell signaling technology II 
α -phospho-MLC 
ser19, 3671 rabbit polyclonal ab, WB/IF Cell signaling technology IV 
α -phospho-
moesin, Thr558 goat polyclonal ab, WB Santa Cruz Biotechnology inc. III 
α -phospho-PKB 
ser473 rabbit polyclonal ab, WB New England BioLabs III 
α -phospho-S6, 
2211 rabbit polyclonal ab, IHC Cell signaling technology  II 
α -phospho-
Smad2 
ser465/467, AB 
3849 
rabbit polyclonal ab, 
WB/IHC Chemicon International II, III 
α -phospho-
tyrosine, 4G10 mouse monoclonal ab, WB Upstate Biotechnologies III 
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α -SM22 goat polyclonal ab, WB Abcam III 
α -a-SMA, a-5691 
mouse monoclonal ab, 
WB/IF/IHC  Sigma II, III 
α -Smad2/3, 
18/Smad2/3 mouse monoclonal ab, IF BD Transduction laboratories III 
α -vinculin, 
hVIN1 mouse monoclonal ab, IF BD Transduction laboratories III  
Table 3. Cells used in this study 
cells description source 
used in 
study 
C2C12 mouse myoblast cell line ATCC I 
COS-7 monkey kidney cells ATCC I 
G361 human melanoma cell line ATCC I 
HeLa human cervical cancer cell line ATCC IV 
MEF primary mouse embryonic fibroblasts 
primary cultures 
prepared by the author III, IV 
MLEC 
mink lung epithelial cells stably transfected 
an expression construct containing a 
truncated PAI-1 promoter fused to the 
firefly luciferase reporter gene. 
provided by Dr. Daniel 
Rifkin 311 II 
U2OS human osteosarcoma cell line ATCC I, IV  
Table 4. short interfering (si) ribonucleic acid (RNA) oligos used in this study 
siOLIGOs description source used in study 
siLkb1 
Lkb1 targeting oligos: J-044342-5, J-
044342-7, J-044342-8 Dharmagon III 
siMRIP 
MRIP targeting oligos: L-014102, J-
014102-09, J-012102-10 Dharmagon IV 
siMYPT1 
MYPT1 targeting oligos: L-011340, J-
011340-07, J-011340-08 Dharmagon IV 
siNT non-targeting oligos: D-001206-13 Dharmagon IV 
siNUAK2 
NUAK2 targeting oligos:L-005374, J-
005374-8, J-005374-9 Dharmagon IV 
 
Table 5. Expression plasmids used in this study 
plasmid description source 
used in 
study 
EXP-AD22 
human fetal brain cDNA library fused to 
GAL DNA binding domain Invitrogen IV 
EXP-AD502 
human liver cDNA library fused to GAL 
DNA binding domain Invitrogen IV 
p(CAGA)12-luc 
12xSmad3 consensus binding site 
(CAGA) drives luciferase expression 
provided by Dr. 
Ten Dijke 312 III 
p21P-Luc 
p21 promoter drives luciferase 
expression 
provided by Dr. 
Laiho 84 I 
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pAHC-Lkb1 mouse Lkb1, N-terminal HA-tag 192 I 
pAHC-LKB1 LKB1, N-terminal HA-tag 192 I 
pAHC-LKB1-
D176N 
LKB1-D176N PJS mutant, N-terminal 
HA-tag 
constructed for 
publication I I 
 
 
pAHC-LKB1-
DNLS 
LKB1, NLS sequence (aa38-43) mutated 
from PRRKRA to AAAKRA, N-
terminal HA-tag 
constructed for 
publication I I 
pAHC-LKB1-KD 
LKB1 in-frame deletion (aa 192-195), 
N-terminal HA-tag 
 constructed for 
publication I I 
pAHC-LKB1-
SL26 
LKB1 in-frame deletion (D303-306), 
PJS mutant, N-terminal HA-tagged  192 I 
pAHC-LKB1-
SL31 
 LKB1 frameshift (aa277-), PJS mutant, 
N-terminal HA-tag 192 I 
pAHC-LKB1-
SL8 
LKB1 frameshift (aa307-) PJS mutant, 
N-terminal HA-tag 192 I 
pAMC-LKB-
G163D 
LKB1-G163D PJS mutant, N-terminal 
MYC-tag 192 I 
pcDNA-
caALK5HA 
constitutively active ALK5, carboxy-
terminal (C-terminal) HA-tag 
provided by Dr. 
Moustakas III 
pcDNA-DEST53-
MBS85 MBS85, N-terminal GFP-tag 
Geneservice, 
Invitrogen, 
publication IV IV 
pcDNA-DEST53-
MRIP MRIP, N-terminal GFP-tag 
Invitrogen, 
publication IV IV 
pcDNA3-
HAp53CT p53 C-terminus, N-terminal HA-tag 
provided by Dr. 
Blandino 313 I 
pcDNA3-mF-
Smad7 Smad7, N-terminal Flag-tag 
provided by Dr. 
Moustakas III 
pcDNA6.2/N-
EmGFP-DEST-
MRIP 
C-terminal MRIP clones identified in 
Yeast two hybrid cloning, N-terminal 
Em-GFP-tag Invitrogen IV 
pCI-Neo Empty vector Promega I 
pCI-Neo-LKB1 non-tagged LKB1 192 I 
pCMX-cyclinE non-tagged Cyclin E 
provided by Dr. 
Piaggio I 
pCS2-XFAST1 non-tagged FAST1 of X. laevis 
provided by Dr. 
Ten Dijke 314 III 
pDEST27-MRIP MRIP, N-terminal GST-tag Invitrogen IV 
pDEST32-
NUAK2 
NUAK2 fused with GAL DNA binding 
domain 
 Invitrogen, 
constructed for 
publication IV IV 
pEBG-NUAK2 NUAK2, N-terminal HA- and GST-tag 
provided by Dr. 
Alessi 199 IV 
pEBG-NUAK2-
T208A 
NUAK2-T208A, N-terminal HA- and 
GST-tag 
provided by Dr. 
Alessi 199 IV 
pEBG-NUAK2-
T208E 
NUAK2-T208E, N-terminal HA- and 
GST-tag 
provided by Dr. 
Alessi 199 IV 
pEBG-QIK 
QIK (SIK2), N-terminal HA- and GST-
tag 
Kindly provided 
by Dr. Dario 
Alessi 199 IV 
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pEGFP-spectrin EGFP-tagged spectrin 
provided by Dr. 
Medema 315 I 
pGL3-ARE-Luc 
Smad2 dependent activin response 
element drives luciferace expression 
provided by Dr. 
Ten Dijke 314 III 
pGL3-BRE-Luc 
BMP-response element drives uciferase 
expression 
provided by Peter 
Ten Dijke 316 III 
pGL3-SM22-Luc 
promoter of SM22 gene (from -447bp to 
+89bp) drives luciferase expression 
provided by Dr. 
Owen III 
pGL3-a-SMA-
Luc 
promoter of a-SMA gene (from -2555bp 
to +2813bp) drives luciferase expression 
provided by Dr. 
Owen III 
pMACS 
surface markers for magnetic cell 
isolation Miltenyi biotech I 
pMT2-HA-AFX AFX, N-terminal HA-tag 
provided by Dr. 
Medema 41 I 
pRLTK-luc Renilla fire fly Promega III 
pTAL-SRE-Luc 
SRE-response element drives the 
luciferase expression Clontech III 
Rc-cycD1-HA Cyclin D1, C-terminal HA-tag 317 I  
Table 6. Mouse strains used in this study 
allele description source 
used in 
study 
Lkb1Lox 
Conditional Lkb1 allele, exons 3-6 are 
flanked by Lox sites and are deleted upon 
Cre-recombinase expression. 
Provided by Dr. 
DePinho and Dr. 
Bardeesy 169 II, III 
Lkb1– 
Lkb1 "null" allele, genomic sequences 
encompassing exons were deleted 
produced in the lab 
of Tomi Mäkelä 172 II, III 
SM22+/Cre 
SM-Cre-ERt2 was created by targeted 
integration of Cre-ERT2 transgene to 
SM22 locus 
Provided by Dr. Feil 
318 II 
AMPKa1– 
AMKPKa1 "null" allele, genomic 
sequences corresponding to aa´s 97–157of 
catalytic domain were deleted. 
Provided by Dr. 
Viollet 274 III 
AMPKa2LoxP 
Conditional AMPKa2 allele, exon C is 
flanked by LoxP sites 
Provided by Dr. 
Viollet 319 III 
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RESULTS AND DISCUSSION 
6. Cytoplasmic LKB1 induces p53 dependent growth arrest (I) 
6.1 LKB1 localizes and is active in both the cytoplasm and the nucleus 
The various patterns of LKB1 localization in mammalian cells and model organisms 
reviewed above (section 4.2) and reported elsewhere 203, 211, 219-223 prompted us to study 
the regulation of LKB1 localization. Consistent with previous reports, LKB1 localization 
in all cell lines studied (U2OS, COS-7, C2C12) was classified into three categories: (i) 
predominantly nuclear, (ii) predominantly cytoplasmic, and (iii) nuclear and cytoplasmic 
(publication I, Figures 1A-B). Surprisingly, most of the LKB1 kinase dead mutants 
(LKB1-KD, LKB1-G163D, LKB1-SL26, LKB1-SL8, and LKB1-SL31, see materials and 
methods for details on mutations) localized exclusively in the nucleus. In contrast, kinase 
dead mutant LKB1-D176N localized in a similar manner to that of wild type LKB1 (I 
Figures 1A, C) as noted in a previous study 222. The nuclear localization of many LKB1 
kinase inactive mutants identified here prompted us to study whether there are differences 
in LKB1 kinase activity in the nucleus and the cytoplasm. Consistent with the 
immunofluorescence (IF) analysis, overexpressed LKB1 was found in comparable 
amounts in the nuclear and cytoplasmic fractions of U2OS and COS-7 cells. Surprisingly, 
nuclear and cytoplasmic LKB1 displayed similar specific autophosphorylation activities 
in vitro (I Figure 1D). Most importantly, endogenous nuclear and cytoplasmic LKB1 
fractions had comparable kinase activities (I Figure 1E). Collectively, these results 
indicate that mammalian LKB1 localizes into both the nucleus and the cytoplasm unlike 
the LKB1 homologues in Caenorhabditis elegans and in Drosophila melanogaster, 
which have been reported to reside exclusively in the cytoplasm and the plasma 
membrane 211, 219, 320. This suggests the conservation of cytoplasmic LKB1 functions 
across the phyla, but not those of the nuclear LKB1. Although the IF studies did not 
provide evidence on plasma membrane localization of LKB1, minute amounts of LKB1 
were found in the membrane fractions of U2OS and COS-7 cells (data not shown). This 
finding is consistent with other studies that used mammalian cells 203, 321.  
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6.2 Cytoplasmic localization of LKB1 correlates with the ability to bind STRAD (I 
and unpublished results) 
Due to the reported re-localization of LKB1 into the cytoplasm in response to interaction 
with STRAD and MO25 194, 196 we wanted to study whether nuclear LKB1 mutants were 
able to bind to STRADα. Gluthathione S-transferase (GST)-pulldown assays of cell 
lysates that overexpressed either the wild type or mutant LKB1 demonstrated strong 
interaction of GST-STRADα and HA-MO25α with the wild type LKB1 or LKB1-
D176N. However, there were no such interactions with LKB1-KD, LKB1-G136D, 
LKB1-SL26, or LKB1-SL8, which demonstrated an inverse correlation between 
exclusively nuclear localization of LKB1 and the ability to bind to STRADα (Figure 6), 
which is consistent with other reports 194, 196. In addition, LKB1 binding to STRADα 
correlated with the ability of MO25α also to bind to STRADα. The stabilizing effect of 
LKB1 on STRADα–MO25α interaction was probably caused by reported interaction 
sites between LKB1 and STRADα and also, between LKB1 and MO25α 193, 198. Our 
results suggest that cytoplasmic localization of LKB1 is dependent on STRADa binding 
but independent of LKB1 kinase activity. It is plausible that additional mechanisms 
including LKB1 phosphorylation by tyrosine kinase FYN 206, the lack of phosphorylation 
by aPKCζ 204 (Figure 7), and the lack of interaction with LKB1 interacting protein (LIP1) 
223 contribute to partial nuclear localization of wild type LKB1 and exclusively nuclear 
localization of some of the LKB1 kinase inactive mutants reported here (Figure 6).  
 
In LKB1 heterozygote (LKB1+/mut) cells the ability of some kinase inactive LKB1 mutants 
to bind to STRAD could result in the limitation of available STRAD and possibly LKB1 
substrates in regard to the wild type LKB1. Consequently, PJS patients or lung 
adenocarcinoma patients that carry such mutations could have more severe tumorigenesis 
than those patients who have the LKB1 kinase inactivating non-STRAD binding 
mutation. Although some initial attempts have been made to correlate LKB1 mutations 
with tumorigenic phenotype of PJS 174, 175 STRAD binding was not included as one of the 
parameters in these analyses. 
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Figure 6: LKB1 mutants that localize in the nucleus do not form a kinase complex with 
STRADα  and MO25α .  
Western blotting analyses of total lysates and GST-pulldown precipitates from 293 cell expressing 
GST-STRADα and HA-MO25α together with EGFP- or HA- epitope tagged wild type LKB1 or 
various kinase inactive mutants as denoted in the figure. LKB1 mutations that are causative for 
nuclear localization (EGFP-LKB1-KD, EGFP-LKB1-G163D, HA-LKB1-SL26 and HA-LKB1-SL8) 
do not interact with GST-STRADα and do not stabilize the interaction between STRADα and 
MO25α. Lower expression levels of EGFP-LKB1-KD and EGFP-LKB1-G136D mutants in 
comparison to wild type and D176N mutant LKB1 are probably a consequence of lack of 
stabilizing effect of LKB1-STRADα complex formation 194. White lines indicate the removal of 
intervening lanes. 
 
Localization of LKB1 into both the cytoplasm and the nucleus could be a consequence of 
LKB1 shuttling between these compartments. Indeed, Lkb1 has been demonstrated to 
have a functional nuclear localizing signal (NLS, I Figures 2A and 221), which has been 
suggested to be masked by STRAD binding 322 (Figure 7). Alternatively, cytoplasmic 
localization of LKB1 could be induced by cytoplasmic retention of the LKB1 222 or by 
nuclear export. Nuclear export could be mediated by a putative nuclear export signal 
(NES) on LKB1 (Figure 7) identified here or by NES sequences on STRADα that have 
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been suggested to be essential for chromosome region maintenance 1 (CRM1) and 
exportin7 dependent nuclear export of LKB1 kinase complex 322. Possible redundancy 
between the two alternative export mediators of LKB1 kinase complex could explain the 
unresponsiveness (I Figure 1F) and the modest nuclear accumulation of LKB1 204, 322 in 
response to Leptomycin b, an inhibitor of CRM1 dependent nuclear export.  
 
With regard to the model by which LKB1 kinase complex formation relocalizes LKB1 
into the cytoplasm and concomitantly induces LKB1 kinase activity, it is surprising that 
our results demonstrate similar LKB1 kinase activities in both compartments. This 
similarity also suggests the existence of LKB1-STRAD-MO25 kinase complex in the 
nucleus. Indeed, a recent study reported the localization of LKB1 and STRADα on the 
promoter regions in the nucleus 323 (Figure 7). Thus it is possible that LKB1 kinase 
complex is not automatically exported from the nucleus but is subjected to an additional 
level of regulation. Moreover, nuclear and active LKB1 could be a consequence of a 
complex formation with STRADα isoforms that lack either the N- and/or the C-terminal 
ends or with STRADβ. These STRADα isoforms and STRADβ lack the characterized 
NES sequences of full length STRADα and thus are expected to be unable to fully 
mediate the LKB1 export out of the nucleus 322, 324. It is also plausible that in some 
contexts LKB1 kinase activity is not dependent on STRAD as has been shown in vivo in 
Caenorhabditis elegans 325. These results and the lack of STRADα mutations in LKB1 
associated tumorigenesis 51, 326, 327, leaves it open as to whether STRAD is essential for 
tumor suppression by LKB1. This conundrum calls for detailed comparative studies on 
cytoplasmic and nuclear LKB1 complexes and their activities in the model system that 
should reflect in vivo tumor suppressive functions of LKB1.  
 
6.3 Cytoplasmic LKB1 is sufficient for growth arrest in G361 melanoma cells 
As LKB1 was found to be active in both the cytoplasm and the nucleus we wanted to 
address the question as to which compartment was it that LKB1 activity suppresses cell 
proliferation. To this end exclusively cytoplasmic LKB1-ΔNLS mutant was expressed in 
the G361 melanoma cell line in which the expression of the wild type LKB1 but not the 
kinase dead LKB1 caused G1 arrest 280. LKB1-ΔNLS mutant induced comparable cell 
cycle arrest to the wild type LKB1 in a kinase dependent manner (I Figure 2C), which 
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suggests that in certain conditions the proposed nuclear functions of LKB1 323, 328 are 
dispensable for LKB1 induced inhibition of cell proliferation. Later on LKB1 kinase 
complex partner STRAD was shown to be essential for G1 growth arrest in G361 cells, 
which is in line with the role of STRAD in inducing cytoplasmic localization and kinase 
activity of LKB1 194. These results do not exclude the possibility that plasma membrane 
localization would be essential for LKB1 induced growth arrest as suggested for the 
regulation of epithelial polarization by the D. melanogaster homologue of LKB1 211. 
However, immunofluorescence staining of the overexpressed LKB1 in G361 cells did not 
find any evidence of membrane localization. Moreover, the LKB1 truncation mutant 
(LKB1 1-416) that lacks the Caax-box, whose farnesylation has been implicated in 
plasma membrane localization 211, 321, induced a comparable increase in G1 cells in 
response to the wild type LKB1 (data not shown).  
 
6.4 LKB1 induced growth arrest in G361 melanoma cells is p53 dependent 
The levels of p21Cip1/WAF1 and p27Kip1 were studied to address the question as to whether 
LKB1 induced growth arrest would be mediated by changes in expression of CDK 
inhibitor. Western blotting analysis revealed an increase in p21Cip1/WAF1 levels specifically 
in LKB1 arrested G361 cells (I Figures 4A-C). The causality of p21Cip1/WAF1 induction 
and LKB1 induced cell cycle arrest was supported by the ability of cyclinD1 and 
CyclinE1 to override LKB1 induced arrest (I Figure 3). This was possibly achieved by 
sequestering surplus p21Cip1/WAF1 and inducing CDK2 activity, respectively. Whether 
LKB1 induced p21Cip1/WAF1 expression and G1 arrest are transient or lead to quiescence, 
melanocyte differentiation, or senescence requires further investigations. 
 
Increased activity of p21P-luciferase reporter construct in LKB1 expressing G361 cells (I 
Figure 5A, B) suggested that LKB1 induced p21Cip1/WAF1 promoter activity. Moreover, 
LKB1 re-introduction induced p21Cip1/WAF1 messenger RNA (mRNA) expression 
consistently in the A549 lung cancer cell line and in MEFs 278, 323. These findings and the 
lack of any known evidence on p21Cip1/WAF1 post-translational stabilization by LKB1 
suggest that the induction of p21Cip1/WAF1 by LKB1 takes place at the transcriptional level. 
p21Cip1/WAF1 is a known transcriptional target of the tumor suppressor p53 68, 89. 
Consistently, transfected dominant negative p53 abolished the LKB1 induced increase in 
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p21P-luciferase activity (I Figure 5C) and prevented the LKB1 induced G1 arrest in G361 
cells (I Figure 5D). These results indicate that p53 is essential for LKB1 induced growth 
arrest in G361 cells and that this possibly occurs via p21Cip1/WAF1 induction. Our results 
do not support a major role for post-translational stabilization of p27Kip1 329 (I Figure 4A) 
though it is plausible that a LKB1 mediated transcriptional repression of cyclinD1 330 
contributes to LKB1 induced cell cycle arrest in G361 cells (I Figure 3).  
 
 


Figure 7: Regulation of LKB1 localization and models of LKB1 induced p21Cip1/WAF1 
expression. A Schematic figure of LKB1 with NLS, putative NES, Caax-box and phosphorylation 
sites thought to be involved in the regulation of LKB1 localization. It has been suggested that 
elements in red enhance nuclear localization, whereas elements in green or yellow promote 
cytoplasmic or plasma membrane association of LKB1, respectively. STRADα with two NES 
sequences is not depicted. B In G361 cells cytoplasmic and most likely STRAD and MO25 bound 
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LKB1 induces the expression of p21Cip1/WAF1 possibly by activating one of the LKB1 substrate 
kinases, which could either (1) re-localize into the nucleus and phosphorylate p53 on p21Cip1/WAF1 
promoter directly or (2) phosphorylate p53 in the cytoplasm from which the p53 would, in turn, re-
localize to the nucleus. In other contexts (3) nuclear LKB1 has been suggested to bind to p53 on 
p21Cip1/WAF1promoter where it is needed for AMPK or possibly SIK1 mediated phosphorylation of 
p53 and histone 2B (H2B) and subsequent p21Cip1/WAF1 expression. The shuttling of LKB1 
between nucleus and cytoplasm is depicted with black dashed arrows. See text for references. 
 
LKB1 and its downstream substrates AMPK and SIK1 have been implicated in the 
phosphorylation of the p53 S15 and S392 323, 331-333 that provide a possible mechanism for 
LKB1 induced p53 dependent cell cycle arrest. Furthermore, both the p53 
phosphorylation and phosphorylation of histone 2B have been implicated in LKB1 
initiated and AMPK-p53 mediated p21Cip1/WAF1 induction 323, 328, 333. In these same reports 
LKB1 was suggested to interact with p53 and AMPK on the p21Cip1/WAF1 promoter region 
in the nucleus in MEFs, U2OS and HCT116 cells 323, 328, 333. As cytoplasmic LKB1 was 
sufficient to cause p21Cip1/WAF1 induction in G361 cells (I, Figure 2C) it is plausible that 
LKB1 could phosphorylate one of the LKB1 substrate kinases in the cytoplasm from 
which activated substrate kinase would relocalize to the nucleus and phosphorylate p53 
on the p21Cip1/WAF1 promoter (Figure 7). Accordingly, AMPK and SIK1 have been 
demonstrated to localize in both the nucleus and the cytoplasm 334, 335. Alternatively, 
LKB1 or its substrate kinases could phosphorylate p53 in the cytoplasm from which p53 
would re-localize to the p21Cip1/WAF1 promoter within the nucleus (Figure 7). Interestingly 
in this regard, LKB1 was reported to induce apoptosis by interaction with p53 in the 
mitochondria of HT1080 cells 336. 
 
When the possible importance of p53 S15 phosphorylation for tumor suppression by 
LKB1 in particular is considered, an interesting parallel is provided by the 
phosphorylation of p53 S15 by the tumor suppressor kinase ATM. Mutations of p53 and 
of ATM are mutually exclusive in lung adenocarcinomas and mutations of either of these 
promote increased mutation rates 51, which suggests that p53 is essential for ATM tumor 
suppression. In contrast, LKB1 and p53 mutations co-segregate in lung adenocarcinomas 
6, 7, 51 and, apparently, LKB1 mutations do not cause increased mutation rates 51. 
Similarly, in cervical cancers LKB1 mutations promote tumorigenesis against a 
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background in which p53 has already been inactivated by the E6 oncogene encoded by 
human papilloma virus (HPV) 177. Furthermore, the synergistic effects of LKB1 and p53 
deletion on gastrointestinal tumorigenesis of mouse models 337, 338 and the lack of 
hamartomatous polyps upon p53 mutations 339-342 suggest that p53 is not the sole 
mediator of tumor suppression by LKB1. However, the correlation of p21Cip1/WAF1 with 
LKB1 levels in p53 wild type but not in mutant pancreatic tumors 343 suggests a model by 
which the relative importance of p53 in LKB1 mediated tumor suppression may vary 
between the tumor types and tumor grade. Moreover, the genetic loss of p53 in LKB1 
deleted tumors may confer additional resistance for, or promote, genetic instability that 
benefits tumor growth.  
7. LKB1 is essential for TGFβ signaling, production and TGFβ dependent 
smooth muscle cell lineage differentiation (II, III) 
Inherited heterozygous mutations of LKB1 cause growth of the hamartomatous 
gastrointestinal polyps with hyperproliferative epithelia. The existence of a prominent 
stromal stalk that is composed of SMC lineage cells and the lack of solid evidence on 
biallelic LKB1 inactivation in epithelia motivated us to address the two following 
questions (i) is the decreased Lkb1 activity in the stromal compartment sufficient for 
polyp formation in vivo? (ii) What are the cellular functions of Lkb1 in SMC lineage 
cells?  
 
7.1 Lkb1 gene deletion in smooth muscle cell lineage causes gastrointestinal 
polyposis in vivo  
To address the role of stromal LKB1 in gastrointestinal tumor suppression the conditional 
Lkb1 allele was deleted in the SM22 expressing SMC lineage cells 318. Development of 
gastrointestinal polyps in Lkb1+/Lox;SM22+/Cre mice was evident from 11 months of age 
onwards leading to death of 12 out of 25 mice by the age of 18 months (II Figures 1A, B). 
Polyps caused by stromal inactivation of Lkb1 were indistinguishable from the polyps 
observed in the PJS mouse model (Lkb1+/-) and also in PJS patients (II Figure 1C and 172), 
suggesting that Lkb1 activity in SMC-lineage cells is tumor suppressive and stromal 
deletion of the Lkb1 gene is sufficient to drive GI polyposis. 
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We attempted to characterize the possible changes in stromal cells upon Lkb1 deficiency 
by quantifying the relative amounts of SMC and myofibroblast. This revealed the 
enrichment of myofibroblasts in polyps (II Figure 2A). Similarly, myofibroblasts were 
enriched in the polyp stroma in Lkb1+/– mice and, importantly, in the polyps of PJS 
patients (II Figure 4A). The enrichment of the myofibroblasts could have been caused by 
the proliferation of the existing myofibroblasts subsequent to Lkb1 deletion or by de-
differentiation of SMCs to myofibroblasts as noted in other diseases such as vascular 
injury 344 and severe lesions of coronary artery 345. 
 
7.2 Lkb1 is required for myofibroblast differentiation 
It has been suggested that SMCs partially develop via the fibroblast-myofibroblast-SMC 
sequence 346-348. Consequently, the primary MEFs are appropriate cell culture model of 
SMC-lineage differentiation as they have been shown to differentiate spontaneously into 
myofibroblasts in response to the tension caused by cell contraction against focal 
adhesions on a rigid cell culture plate 349-352. Here control and Lkb1 deleted primary 
MEFs were created by adenoviral expression of LacZ or Cre-recombinase in cell culture. 
The control MEFs displayed robust expression of myofibroblast markers α-SMA and 
SM22, whereas their expression was lost in the majority of Lkb1-/- MEFs (III Figure 2B, 
C). These findings were consistent with a deficient SMC lineage differentiation upon 
Lkb1 inactivation.  
  
Actin stress fibers in Lkb1-/- MEFs were studied in order to map which stage of the 
myofibroblast differentiation process was deficient upon Lkb1 deletion. The formation of 
actin stress fiber bundles precedes α-SMA expression during myofibroblast 
differentiation and defines a differentiation stage named the proto-myofibroblast (see 2.3) 
132. Actin stress fibers were lost in most of Lkb1-/- MEFs (Figure 8) and this loss was 
accompanied by deficient focal adhesion maturation (III Figure 2D). Moreover, 
contractility of Lkb1-/- MEFs was dramatically decreased as measured by their ability to 
deform silicon substrate in cell culture (III Figures 2D, E). Comparable focal adhesion 
kinase (FAK) activation in response to cell attachment in the control and Lkb1-/- MEFs 
(III Figure 3A) suggest that initial cell adhesion and focal complex formation were not 
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affected by Lkb1 deletion. Consequently, defects in factors that promote cell contractility 
and actin stress fibers were more likely to contribute for the deficient myofibroblast 
differentiation of Lkb1-/- MEFs.    
 
Figure 8: Attenuated actin stress fibers in Lkb1-/- MEFs. Acute deletion of LKB1 in primary 
MEFs led to the loss of actin stress fibers as seen by the decreased staining of actin fibers by 
phalloidin (green). Nuclei are stained with hoechst (blue).  
7.3 Lkb1 potentiates Smad dependent TGFβ signaling in primary fibroblasts 
TGFβ signaling drives the differentiation of myofibroblast and SMCs in cell culture and 
in vivo 353, 354. Thereby, TGFβ signaling status was tested both in our in vivo and cell 
culture models in which the Lkb1 gene deletion was associated with deficient SMC-
lineage differentiation. Interestingly, phosphorylation of Smad2 was compromised in 
Lkb1 deleted MEFs (III Figure 1B). Consistently, Smad2/3 were mostly cytoplasmic (III 
Figure 1C) and Smad3 and Smad2 dependent transcription were attenuated Lkb1-/- MEFs 
as monitored by (CAGA)12-Luc and activin response element (Are)-Luc reporters (III 
Figure 1A), respectively. Importantly, (CAGA)12-Luc activity was significantly decreased 
in Lkb1+/- MEFs (III Figure 1A), which are similar to mesenchymal cells in PJS polyps in 
regard to the LKB1 genotype 262. In support of these results, p-Smad2 levels were 
decreased in Lkb1 deficient but not in adjacent Lkb1 wild type stromal cells in the polyps 
of Lkb1+/Lox;SM22+/Cre mice in vivo (II Figure 2G-I and 3D). These results are further 
supported by the demonstration of decreased levels of plasminogen activator inhibitor 
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type 1 (PAI-1), a TGFβ target gene, by three independent Lkb1-/- MEF studies (our 
unpublished observation and 169, 355) and also a study in which LKB1 was downregulated 
in an immortalized HUVEC cell line 356.  
 
TGFβ signaling activity of control and Lkb1-/- MEFs were measured in response to 
exogenous TGFβ1 (1ng/ml, 24h) or constitutive activation of TGFβRI ALK5 to map the 
point of interaction between LKB1 and TGFβ signaling pathways in Lkb1-/-. Although 
(CAGA)12-Luc reporter activity was induced in Lkb1-/- MEFs by exogenous TGFβ and 
constitutively active ALK5, it did not reach the levels observed in treated control MEFs 
(III Figure 1D). This result suggests that Lkb1 potentiates but is not essential for the 
TGFβ pathway activity and that Lkb1 interacts with the TGFβ signaling pathway 
downstream of receptor activation. In consideration of LKB1 substrates mediating 
modulation of TGFβ signaling activity by LKB1, it is interesting that LKB1 substrate 
NUAK2 has been reported to interact with TGFβRI, Smad2 and Smad4 357 and may thus 
promote full activation of Smad signaling. Keeping in mind reported interactions between 
LKB1 and p53 (see 6.4), it is intriguing that p53 has been thought to be essential for full 
Smad dependent transcriptional activation of p21 expression 358. Thus p53 activation via 
phosphorylation of p53-S15 and p53-S392 by LKB1 or its substrate kinases could 
contribute to the regulation of Smad dependent promoter activation. On the other hand, 
activation of TGFβ signaling upon LKB1 expression could contribute to an increased p21 
expression in conditions of high LKB1 levels in cell culture (I Figures 4A-C) and in vivo 
278, 343. 
 
In contrasting the role of LKB1 as an activator of TGFβ signaling in primary MEFs (III 
Figure 1) and HUVEC cells 356, decreased LKB1 activity was found to be associated with 
enhanced TGFβ signaling in multiple epithelial cell lines, HepG2 cell line of hepatocyte 
origin, and C2C12 cell line of mesenchymal origin 355, 359. This association might 
possibly provide an explanation for an induction of EMT and increased cell motility in 
cell culture 299, 355, 359 and in lung adenocarcinomas 6, 359 upon Lkb1 deficiency. 
Suppression of TGFβ signaling by LKB1 in epithelial cells might be mediated by the 
interactions between LKB1, Smad4 binding protein LIP1 and Smad4 355 or by LKB1 
substrate kinase SIK1 264.  SIK1 was reported to be induced in response to the activation 
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of TGFβ signaling and to mediate downregulation of TGFβRI/ALK5, which would create 
a negative feedback loop in TGFβ signaling 264. 
 
7.4 TGFβ mediates Lkb1 function in regulation of myofibroblast differentiation 
Lkb1-/- MEFs were treated with exogenous TGFβ to directly address whether attenuation 
of TGFβ signaling was causative for myofibroblast dedifferentiation of Lkb1-/- MEFs. 
Indeed, TGFβ induced the α-SMA and SM22 expression in Lkb1-/- MEFs to levels 
comparable with non-treated control MEFs (III Figures 4A, B). Concomitantly, actin 
stress fibers, maturation of focal adhesions (III Figure 4C), and contractility of Lkb1-/- 
MEFs were rescued. SMC-lineage components including α-SMA and SM22 are targets of 
Smad dependent transcription 360-365. Decreased α-SMA-luciferase and SM22-luciferase 
reporter activities in Lkb1-/- MEFs in comparison to control and TGFβ treated Lkb1-/- 
MEFs (III Figure 4D, E) suggest that deficient TGFβ dependent transcription contribute 
to attenuated myofibroblast differentiation subsequent to Lkb1 inactivation. The ability of 
TGFβ to rescue both proto-myofibroblast characteristics as determined by actin stress 
fiber expression and myofibroblast characteristics measured by α-SMA and SM22 
expression (III Figure 4A-E) supports the idea that LKB1-TGFβ signaling promotes 
myofibroblast differentiation at several levels. Such levels possibly include post-
translational modification of contractile machinery via activation of RhoA 137, 139, 366. 
 
The in vivo study, for which Lkb1 deletion in SM22 positive cells resulted in increased 
ratio of myofibroblasts to SMC (II Figure 2A), and also the cell culture study, in which 
exogenous TGFβ rescued the loss of myofibroblast marker expression in Lkb1-/- MEFs 
(III Figure 4A-E), suggest the dedifferentiation of SMC lineage cells is a possible cause 
of PJS polyposis. Similarly, it has been suggested that in breast cancer vascular SMCs 
contribute to myofibroblasts 367. In malignant tumors myofibroblasts also known as 
cancer associated fibroblasts have been thought to partly originate from fibroblasts in 
response to increased PDGF secretion by tumorigenic epithelia and by the subsequent 
increase in TGFβ secretion emanating from infiltrating myeloid cells 368, 369. In addition, 
other sources of myofibroblasts/cancer associated fibroblast, such as epithelial cells 
undergoing EMT 370, 371, have been suggested. Nevertheless, our model on SMC 
dedifferentiation as causative for enrichment of myofibroblasts in the PJS polyps is 
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supported by following results: 1) α-SMA negative stroma, which most likely represents 
fibroblasts and which was adjacent to Lkb1 deleted myofibroblasts, lacked deleted Lkb1 
allele (II Figures 2G-I) and 2) Lkb1 deficient GI epithelial cells have normal polarity in 
vivo 372, 373. Unlike in our cell culture model in which Lkb1 deletion in early passage 
MEFs did not cause alterations in cell proliferation (III Figure S1), the dedifferentiation 
in vivo could be associated with an increased proliferation of SMC lineage cells 374, 375. 
 
Recently, Lkb1 has been implicated as a factor in the differentiation of neurites 213, 214, 
hematopoietic cells 376-378 and gastrointestinal epithelial cells 372, 373. In addition it has a 
possible role in the lineage choice of lung cancer progenitor cells in a mouse model 6. In 
contrast, Lkb1 inactivation in keratinocytes, striated muscle, heart and liver have provided 
no evidence on defective differentiation 237, 239, 292, 379. Collectively, these studies support 
the concept of LKB1 being a context specific gatekeeper of differentiation and suggest 
differentiation defects as a possible cause for LKB1 associated tumorigenesis also in 
other tissues than the GI-tract. 
 
7.5 Decreased secretion of TGFβ by Lkb1 deficient stroma as a possible mechanism 
of epithelial hyperproliferation 
Our model of the dedifferentiation of SMCs under condtions of LKB1 deficiency could 
explain the development of the prominent stromal stalk in PJS polyps but do not provide 
a direct mechanism for the hyperproliferation of adjacent polyp epithelia. Interestingly, 
there is a positive feedback loop in TGFβ production 120-123 and, consistently, TGFβ1 
mRNA levels were decreased both in Lkb1-/- MEFs and in polyps of Lkb1+/Lox;SM22+/Cre 
mice (II Figure 3M). Consequently, TGFβ secretion, as measured by the PAI-1 luciferase 
(PAIL) assay, was attenuated in Lkb1-/- MEF cultures (II Figure 3I). These findings imply 
that decreased TGFβ secretion by Lkb1 deficient stromal cells could induce epithelial 
proliferation 140, 380 observed in vivo in Lkb1+/Lox;SM22+/Cre mice (II Figure 3G-I) and PJS 
polyps 300. Consistently, p-Smad staining in epithelial cells adjacent to Lkb1 deleted 
stroma was decreased and coincided with the increased expression of Ki-67, which is a 
marker of cell proliferation 381 (II Figure 3D-I). Additionally, the possible attenuation of 
Lkb1 deficient stromal cell contractility in vivo could reduce amounts of activated TGFβ 
available for the epithelial cells (see 2.1) 100, 101, 133. Whether attenuated TGFβ signaling 
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in the epithelia could contribute to epithelial differentiation defects noted in 
Lkb1+/Lox;SM22+/Cre and Lkb1+/– mice 373 in addition to PJS patients, requires further 
investigation. 
 
Our studies suggest a non-autonomous role for LKB1 in the suppression of epithelial 
hyperproliferation in the GI-tract. Moreover, they are in contradiction to the hypothesis 
that proposes polarity defects of epithelial cells and subsequent relapse as causative of 
PJS polyposis 300, 301. In support of our model, Lkb1 deletion in the gastrointestinal 
epithelia has not been reported to lead to tumorigenesis 372 and thus LKB1 could be 
categorized as a landscaper tumor suppressor similar to what has been suggested for 
Smad4 105. Our results together with the induction of GI tumorigenesis upon Smad4 
deletion in the T cells 382 and the deletion of TgfβrII in fibroblasts 108 provide novel 
examples of the active role of stroma in the suppression of tumorigenesis. In contrast to 
its landscaper function, LKB1 has been shown to suppress tumorigenesis in a cell 
autonomous fashion in several tissues: sporadic mutations of LKB1 have been found in 
tumor cells themselves in cervical cancer 177, non small cell lung adenocarcinoma 6, 7 and 
mouse model of induced skin tumorigenesis 237. This in combination with cell type 
specific regulation of TGFβ signaling by LKB1 reported in this study and in other studies 
355, 356, 359 underlines the context specificity of LKB1 tumor suppression.  
 
7.6 Is AMPK involved in LKB1 tumor suppression in the gastrointestinal tract? 
Although decreased AMPK activity is evident in several LKB1 mutated tumors, mouse 
models, and tumor cells 6, 235-238, it remains unclear whether the deregulation of AMPK is 
causative of tumorigenesis. Increased levels of phosphorylated ribosome subunit S6 in 
the PJS polyp epithelia have been used to suggest that attenuated AMPK activity as a 
cause for PJS 229, 383 (Figures 1 and 4). However, increased levels of phosphorylated S6 
are most likely secondary to that of polyp growth or caused by unidentified additional 
mutations other than those of Lkb1 as similar increase in epithelial p-S6 levels was 
observed in mice in which Lkb1 was inactivated only in the stromal cells (II Figures S2E-
F). Thus the decreased polyposis of Lkb1 heterozygote mice upon mTOR inhibitor 
rapamycin 383, 384 does not provide evidence for a causal association between the 
decreased AMPK activity and polyposis. Of course this does not rule out the possibility 
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that AMPK would contribute to epithelial hyperproliferation or induction of stromal stalk 
noted in PJS polyps. Intriguingly, mTOR activation has been implicated in the 
dedifferentiation of vascular smooth muscle cells 385. Furthermore, TSC1/2 complex, a 
target of AMPK, is essential for actin stress fiber regulation in MEFs 386 However, our 
results showed normal actin stress fibers (data not shown) and myofibroblast 
differentiation in AMPK deficient primary MEFs (III Figure S2), which implies that 
AMPK does not regulate actin stress fibers and differentiation via phosphorylation of 
MLC 310 or other targets in SMC-lineage cells. Thus deficient actin stress fibers in 
TSC1/2 attenuated MEFs might reflect deficient PTEN signaling as PTEN deleted MEFs 
were reported to have enhanced myofibroblast differentiation 387. Moreover, the lack of 
AMPKα1 and α2 mutations in PJS patients 262 suggests that either AMPKα1 or α2 are not 
major mediators of tumor suppression by LKB1 in these tissues or alternatively that 
AMPKα1 and α2 are redundant. The potential tumor suppressive role of AMPK in the GI 
tract could be addressed by studies on AMPKα1-/- or α2 -/- mice or by stroma-specific 
deletion of both alleles. 
 
8. LKB1 substrate NUAK2 promotes actin stress fibers (IV) 
8.1 NUAK2 interacts with actin binding myosin phosphatase Rho-interacting 
protein (MRIP) and localizes to the actin stress fibers 
The possible involvement of LKB1 in promoting actin stress fibers and contractility (see 
results 7.2 and 7.4) suggests that LKB1 might either positively regulate RhoA signaling, 
which promotes contractility, or negatively regulate MLCP, which counteracts the RhoA 
pathway by dephosphorylation of MLC 388 (see 2.3).  
 
In regard to the involvement of the LKB1 substrate kinases in actin stress fiber 
regulation, it was of great interest that NUAK2 interacted with the actin binding protein 
MRIP (also known as p116rip) in two independent yeast two hybrid screens carried out in 
our laboratory (IV Figure 1A). A total of 26 out of 28 clones that interacted with NUAK2 
encoded for various C-terminal fragments of MRIP. MRIP is a large protein that binds to 
actin with its N-terminus and to MYPT, a subunit of MLCP, with its C-terminus. Thus it 
functions as an adapter between the actin cytoskeleton and MLCP. MRIP has been 
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suggested to be crucial for MLCP activity towards MLC as the overexpression of MRIP 
attenuated and downregulation induced actin stress fibers 389-391.  
 
The established role of MRIP with regard to actin fibers prompted us to study whether 
NUAK2 could localize onto the actin stress fibers. The interaction of NUAK2 with MRIP 
was studied in the HeLa cell line in which the earlier characterization of MRIP had been 
carried out 389, 392. The co-localization of epitope tagged NUAK2 and MRIP on the stress 
fibers (IV Figure 1D) strongly supported the interaction observed in the yeast two hybrid 
assay. Furthermore, GST-pulldown assays demonstrated NUAK2 and MRIP interaction 
in the soluble pool of the cell lysates (IV Figures 1B, C). Localization of NUAK2 on 
actin stress fibers was MRIP dependent as demonstrated by the loss of stress fiber 
localization of NUAK2 upon MRIP downregulation (IV Figures 3A, B and S3A, B). 
Despite extensive studies on LKB1 localization using several cell types there are no 
reports of LKB1 localizing on actin stress fibers, which suggests that either LKB1 
localization on actin stress fibers is transient or that NUAK2 is activated by LKB1 in the 
soluble pool of cytoplasm from which activated NUAK2 would re-localize to the stress 
fibers. Consistent with possible dynamic NUAK2 localization mechanism, overexpressed 
NUAK2 was observed both in the cytoplasm and the nucleus in addition to the actin 
stress fibers (IV Figures S2, S3A).  
 
8.2 NUAK2 promotes actin stress fibers in kinase independent and dependent 
manner by inhibiting myosin light chain phosphatase (MLCP) 
In order to study whether NUAK2 contributed to the regulation of actin stress fibers, 
phalloidin intensities of NUAK2 overexpressing HeLa cells were quantified. 
Interestingly, wild type NUAK2 increased actin stress fibers significantly. Apparently 
this increase was mediated in a kinase activity independent manner as HeLa cells do not 
express LKB1. Moreover, kinase deficient T-loop mutant NUAK2-T208A 199 promoted 
stress fibers in a comparable manner to wild type NUAK2 (IV Figures 1D, E and S1). 
Expression of constitutively active NUAK2-T208E mutant 199 caused a further increase in 
phalloidin intensity in comparison to the wild type and T208A mutant NUAK2 (IV 
Figures 3D, E and S1). This suggested partially kinase independent and kinase dependent 
functions for NUAK2 in the regulation of actin stress fibers in HeLa cells. Consistent 
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with the stress fiber induction by NUAK2 overexpression, NUAK2 downregulation led to 
the attenuation of stress fibers that was concomitant with the decrease in phosphorylated 
MLC (IV Figures 4A-E). This finding together with the NUAK2 interaction with MLCP 
adaptor MRIP suggests that NUAK2 might inhibit MLCP activity. 
 
We investigated whether NUAK2 might inhibit MLCP. Therefore, we acutely inhibited 
the MLC kinase ROCK by using the specific inhibitor Y27632 393, 394. ROCK inhibition 
in the control cells led to the rapid loss of stress fibers. This was most likely due to the 
lack of ongoing phosphorylation of MLC and thus domination of MLC 
dephosphorylation by MLCP 392. Thus changes in MLCP activity should be seen as 
changes in the kinetics of loss of stress fibers. Expression of NUAK2 caused the 
resistance of central stress fibers to Y27632 treatment (IV Figures 4A, B) but not to 
cytochalasin D treatment, which prevents fiber formation in an MLCP independent 
manner by binding to actin monomers 395. Consistent with a role of NUAK2 in the 
inhibition of MLCP via MRIP interaction, actin stress fiber disruption and decreased 
levels of phosphorylated MLC upon NUAK2 downregulation were dependent both on 
MRIP and MYPT1 (IV Figures 7A-D). These studies identified MRIP as a hub at which 
both negative and positive MLC regulation are integrated.  
 
Other possible LKB1 downstream pathways involved in actin stress fiber regulation 
include RhoA activation by RhoA GTP exchange factor (RhoA-GEF) DBL (also known 
as MCF2). Overexpressed LKB1 was suggested to interact with DBL in HeLa cells and 
induce actin stress fiber formation in an LKB1 kinase activity independent manner 
(Figure 9) 396. In addition, the LKB1 substrate AMPK has been implicated in the direct 
phosphorylation of MLC in Drosophila melanogaster 310 (Figure 9, see 5.2). It is 
plausible that one or multiples of these LKB1 regulated signaling pathways could 
contribute to the loss of stress fibers in Lkb1 deleted MEFs (III Figure 2D). However, 
normal phosphorylation levels of ROCK target moesin in Lkb1-/- MEFs 397, 398 (III Figure 
3C) in addition to normal actin stress fibers (data not shown) and myofibroblast 
differentiation in AMPK deleted MEFs (III Figure S2) suggest that in MEFs it is NUAK2, 
instead of DBL or AMPK that should be considered as a candidate mediator of LKB1 
activity in actin stress fiber regulation.  
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Our observation of the TGFβ signaling mediated induction of actin stress fibers by Lkb1 
in MEFs and the involvement of LKB1 substrate kinase NUAK2 in the positive 
regulation of actin stress fibers in HeLa cells support the idea that NUAK2 could mediate 
LKB1 dependent regulation of TGFβ signaling. Interestingly, TGFβ induced RhoA-
ROCK activity in differentiating SMCs was suggested to be essential for the nuclear 
localization of Smads and Smad dependent promoter activation 366. Therefore it is 
plausible that the phosphorylation of MLC is a prerequisite for the proper activation of 
Smads in differentiating SMCs, though this hypothesis has not been tested yet. Thus 
positive regulation of MLC phosphorylation by kinase active NUAK2 could provide the 
mechanism for the potentiation of TGFß signaling by LKB1 (Figure 9). Alternatively, 
NUAK2 could affect TGFβ signaling via interactions with the TGFβ signaling pathway 
components 357.  
8.3 Identification of a positive feedback loop between actin stress fibers and NUAK2 
expression 
The partially kinase independent function of NUAK2 in promoting actin stress fibers 
suggested that NUAK2 expression levels can act as a potential means of regulation of 
NUAK2 function. Indeed, NUAK2 mRNA and protein levels were low in serum starved 
cells in which the stress fibers were attenuated but high in the presence of prominent actin 
stress fibers induced by one hour of treatment with 10% serum (IV Figures 5A-E). Direct 
evidence on the role for actin in regulating NUAK2 levels was provided by the following: 
decreased NUAK2 mRNA levels in response to one-hour of treatment with ROCK kinase 
inhibitor Y27632, myosin 2 inhibitor blebbistatin, or actin binding drug cytochalasin D, 
all of which caused a rapid loss of actin stress fibers (IV Figures 5A-E). The rapid 
regulation of NUAK2 mRNA in response to altered actin fiber dynamics suggests the 
existence of actin responsive elements on the NUAK2 promoter. Potential transcription 
factors involved in mediating the effects of altered actin dynamics on gene expression 
include: a complex between serum response factor (SRF) and megakaryoblastic leukemia 
1 (MAL), which is inhibited by monomeric actin and thus activated in response to actin 
polymerization 399, and also the transcriptional repressor yin yang 1 (YY1), which is 
inhibited upon actin fiber formation 400. Our current studies are aimed to resolve whether 
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these TFs are involved in the regulation of NUAK2 expression levels. Increased 
expression of NUAK2 in response to prominent actin stress fibers with the induction of 
actin stress fibers in response to NUAK2 expression suggests the existence of a positive 
feedback loop, which promotes the maintenance of actin stress fibers. Previously, similar 
positive feedback loops had been suggested to involve structural components of actin 
cytoskeleton, such as actin and tropomyosin 401, 402. However, to the best of the author’s 
knowledge NUAK2 is the first actin stress fiber regulating kinase whose expression 
levels rapidly respond to dynamic changes in the actin cytoskeleton. 
 
Recently, NUAK1 was shown to bind to PP1 and phosphorylate MYPT1 on three sites in 
the soluble fraction of cells which led to the sequestration of MLCP by 14-3-3 403. The 
findings of their study combined with our results suggest a model by which NUAK2 
inhibits MRIP bound MLCP in a partially kinase independent manner in the presence of 
abundant actin stress fibers whereas activation of NUAK1 by LKB1 might allow local 
MLCP inhibition in conditions of low actin fiber content (Figure 9). Obviously these 
mechanisms between NUAK1 and NUAK2 might be partially redundant (see 4.3) as 
suggested by our observation of further increase in stress fibers by constitutive activation 
of NUAK2 (NUAK2-T208E) in comparison to that found for the wild type NUAK2 (IV 
Figures 1E and S1). 
 
UNC-82 a homologue of NUAK2 and NUAK1 in Caenorhabditis elegans is essential for 
muscle integrity in vivo 404, which suggests a general role for NUAK2 in the regulation of 
actomyosin fibers. Interestingly, the expression of MRIP and NUAK2 were induced by 
the 18-hour TGFβ treatment in epithelial MTLn3E cells 125. Similar to that found for 
RhoA/C MRIP was required for TGFβ dependent disruption of epithelial cell-cell 
junctions and the retraction of the tail end of motile cells 125. These results together with 
the finding in this study of an identified NUAK2–MRIP interaction suggest that NUAK2 
is a potential inducer of EMT, at least in MTLn3E cells (Figure 10). Consistently, meta-
analysis of the EST-database revealed a high NUAK2 expression in ovarian cancer and 
peritoneal adenocarcinoma samples that represent highly invasive cancers (publication 
III, www.genesapiens.org, and 405). In contrast to these, LKB1 mutations have been 
associated with increased invasiveness of tumors, which suggests that one or several 
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LKB1 substrate kinases normally inhibit EMT 6, 177, 359 (see literature review 3.3, Figure 
10). The discrepancy between reported inhibition of tumor invasiveness by LKB1 and 
potential promotion by NUAK2 might be explained by a cell type specific regulation of 
TGFβ signaling by LKB1 223, 355, 359 (see results & discussion 7.3, Figure 10). 
Accordingly, LKB1-NUAK2-MRIP could promote the invasiveness of cells in which 
LKB1 potentiates TGFβ signaling and inhibit the invasiveness of cells in which LKB1 
suppresses TGFβ signaling. Alternatively, MRIP dependent induction of EMT could 
represent NUAK2 kinase independent function (Figure 10). 
 
 
 
Figure 9: Actin stress fibers and TGFβ pathway activity are possible targets of LKB1-
NUAK2 signaling.  
(1) LKB1 substrate kinase NUAK2 is able to inhibit PP1 (MLCP) activity in a kinase independent 
manner and possibly in kinase dependent manner via the phosphorylation of MYPT on three 
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amino acid residues, which leads to the sequestration of MLCP by 14-3-3. Alternative 
mechanisms of actin fiber regulation by LKB1 include (2) the direct phosphorylation of MLC by 
activated AMPK and (3) LKB1 binding to RhoA-GEF DBL and thus the activation of RhoA-ROCK 
signaling, which leads to phosphorylation of MLC. (4) Co-regulation of TGFβ signaling and actin 
fibers by LKB1 suggest it is plausible that LKB1-NUAK2 induces TGFβ signaling by affecting 
actin cytoskeletal dynamics, which would be consistent with the reported observation of RhoA 
induced Smad signaling. 
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PERSPECTIVES  
Studies presented here revealed possible links between LKB1 and two major tumor 
suppressive pathways namely, the p53 and the TGFβ signaling pathways. First, the 
observation on LKB1 induced p53 dependent and p21 associated G1 arrest in G361 cells 
have been followed by several publications that suggest p53-S15 phosphorylation as a 
link between LKB1 and p53 323, 331, 333. Due to the discrepancies in the in vivo evidence 
on the importance of p53 as a downstream target of LKB1 51, 343 (see 6.4) further studies 
on the possible LKB1–p53 link in Lkb1 associated tumor models are required. The effect 
of p53-S15A knock in (S18A in mice) 406 in model mice of KRAS driven lung cancer 407, 
408 and studies on possible synergistic effects of p53-S15A knock-in and Lkb1 deletion in 
polyposis of GI tract (169-172 and this study), tumorigenesis of lung 6 and tumorigenesis of 
pancreas 238 could reveal whether p53-S15 phosphorylation is downstream of LKB1 
tumor suppression. Second, the potentiation of TGFβ signaling in primary mesenchymal 
cells by Lkb1 and the data of recent studies suggesting TGFβ suppression by LKB1 in 
other model systems 355, 359 links these two tumor suppressive pathways. It is intriguing 
that in mesenchymal cells LKB1 may enhance TGFβ signaling and thus suppress 
epithelial proliferation via increased secretion/activation of TGFβ. On the other hand, 
LKB1 could suppress the adverse effect of TGFβ signaling (EMT) in epithelia as 
suggested by the increased TGFβ signaling and metastatic capability of Lkb1 deficient 
lung tumors 6, 359 (Figure 10). Indications of LKB1 in the regulation of TGFβ signaling 
calls for further studies on the contribution of LKB1 in tumorigenesis of colon and 
pancreas in which frequent alterations of TGFβ signaling have been reported 409-411. 
Third, these studies are the first to demonstrate the dependency of actin stress fibers on 
Lkb1 and its substrate kinase NUAK2. The critical role of stress fibers in cell 
contractility associates LKB1 with the remodeling of ECM and cell motility. These 
studies could also provide insight into the mechanisms to explain earlier observations in 
which regulation of polarity by LKB1 has been implied to be partially dependent on the 
actin cytoskeleton 194, 310. The intriguing connection of NUAK2 with both TGFβ 
signaling 125, 357 and actin cytoskeleton warrants further studies on the possible role of 
NUAK2 as a mediator of Lkb1 and TGFβ dependent regulation of the actin cytoskeleton 
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and mesenchymal cell differentiation (Figures 9 and 10). Furthermore, the finding of 
increased adenoma and aberrant crypt foci formation in the large intestine of 
azoxymethane treated NUAK2 heterozygote mice in comparison to wild type mice 
supports a tumor suppressive role for NUAK2 in the initiation of tumorigenesis 276. The 
combination of NUAK2 overexpression or deficiency with Lkb1 associated tumor prone 
mouse models (236-238, 412 and this study) are essential to clarify whether NUAK2 
contributes to tumor suppression by LKB1.  
 
Future studies will expand our knowledge on LKB1 signaling network. It is possible that 
all LKB1 substrate kinases have already been identified as LKB1 does not phosphorylate 
maternal embryonic leucine zipper kinase (MELK), NIM1 and testis-specific 
serine/threonine kinases (TSSK1-4) 199, 234, all of which are most closely related to the 
known 14 LKB1 substrate kinases. Instead, studies on context dependent activation of 
known LKB1 signaling pathways could shed light on the mechanism of LKB1 tumor 
suppression. There is a possibility that LKB1 could function as a hub in which 
extracellular and intracellular cell growth regulating cues are integrated (Figure 10). It 
has been suggested that growth factor responsive ERK inhibits LKB1 activity by 
phosphorylation of LKB1-S325 215. In contrast, phosphorylation of LKB1-S428 by lipid 
and hormone sensitive PKA and other kinases was essential for LKB1 activity 203, 211. On 
the other hand, LKB1 signaling is responsive to cell intrinsic stress as an increase in 
AMP levels potentiates the activation of AMPK by LKB1 246. Moreover, various cellular 
stresses cause the upregulation of LKB1 substrate kinase NUAK2 260. Technologies such 
as fluorescence resonance energy transfer and the availability of phospho specific 
antibodies enable spatiotemporal studies on the activation of particular LKB1 signaling 
pathways in response to specific stimuli involved in tumorigenesis.   
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Figure 10. Working model: LKB1 signaling circuitry in tumor suppression.  
The studies in this thesis and the studies reported elsewhere suggest the following: 1) NUAK2 
should be considered as a possible LKB1 substrate kinase that mediates cell contraction, TGFβ 
signaling, and SMC lineage differentiation that are induced by LKB1 in mesenchymal cells of the 
stroma. 2) LKB1 increases amounts of active TGFβ and thus also induces TGFβ signaling in 
adjacent epithelial/tumor cells via the enhanced contractility and TGFβ auto-loop. This event may 
lead to the inhibition of cell proliferation or induction of EMT in a context dependent manner. 3) 
LKB1 in epithelial cells may concomitantly inhibit tumor cell proliferation by activating p53 possibly 
through AMPK or SIK1. 4) LKB1 may inhibit EMT by suppressing TGFβ signaling through 
NUAK2, SIK1 or one of the other substrates. In contrast to suppression of EMT by LKB1, it is 
plausible that in some conditions NUAK2 should be considered as a candidate inducer of EMT. It 
is possible that NUAK2 does this in an LKB1 independent manner (see 8.3). Signaling activity of 
LKB1 can be regulated by both extra- and intracellular cues. 5) Extracellular cues may include 
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mitogenic growth factors, lipids, and hormones whereas 6) intracellular stress signals contribute 
to activation of LKB1 signaling via increased AMP (AMPK) or LKB1 substrate kinase levels 
(NUAK2).  
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